Document:

EX-10.28

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Exhibit
10.28 
 EXCLUSIVE LICENSE AGREEMENT 

for INSTITUTIONS’ TECHNOLOGY 

“Compositions & Methods for Altering Second Messenger Signaling” 

Reference Numbers: 
 Rutgers:
L2015-0995_LFSC 
 Rockefeller: RU 1136 

University of Bonn: V-20141215-0766 

MSK: SK2014-1899 

 TABLE OF CONTENTS 
  

			
		
	 PREAMBLE
		
		
	 ARTICLE I DEFINITIONS
		1
		
	 ARTICLE II GRANT
		5
		
	 ARTICLE III SUBLICENSES
		6
		
	 ARTICLE IV DILIGENCE
		6
		
	 ARTICLE V PAYMENTS
		8
		
	 ARTICLE VI REPORTS AND RECORDS
		11
		
	 ARTICLE VII PATENT PROSECUTION
		12
		
	 ARTICLE VIII INFRINGEMENT
		13
		
	 ARTICLE IX CONFIDENTIALITY
		15
		
	 ARTICLE X INDEMNIFICATION, PRODUCT LIABILITY
		16
		
	 ARTICLE XI REPRESENTATIONS, WARRANTIES AND DISCLAIMERS
		17
		
	 ARTICLE XII EXPORT CONTROLS
		18
		
	 ARTICLE XIII NON-USE OF NAMES
		18
		
	 ARTICLE XIV PUBLICATION
		19
		
	 ARTICLE XV ASSIGNMENT
		19
		
	 ARTICLE XVI TERMINATION
		19
		
	 ARTICLE XVII NOTICES AND OTHER COMMUNICATIONS
		22
		
	 ARTICLE XVIII MISCELLANEOUS PROVISIONS
		23

  

			
	Exhibit A		LICENSED RIGHTS – PATENT RIGHTS AND KNOW-HOW
		
	Exhibit B		KNOW-HOW
		
	Exhibit C		ADURO PROPRIETARY CYCLIC DINUCLEOTIDE STRUCTURES
		
	Exhibit D		DEVELOPMENT PLAN

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -i- 

 This Exclusive License Agreement is effective as of December 18, 2014 (“Effective
Date”), and is by and between Memorial Sloan Kettering Cancer Center, a New York not-for-profit corporation with principal offices at 1275 York Avenue, New York, NY 10065 (“MSK”), The Rockefeller University, a New York
not-for-profit corporation with principal offices at 1230 York Avenue, New York, NY 10065, Rutgers, The State University of New Jersey, having its statewide Office of Technology Commercialization at 3 Rutgers Plaza, New Brunswick, New Jersey
08901, and University of Bonn (“UB”), all of which will be collectively referred to as “INSTITUTIONS” and Aduro Biotech, Inc., a corporation with principal offices located at 626 Bancroft Way, #3C, Berkeley, CA
94710 (“LICENSEE”). INSTITUTIONS and LICENSEE are sometimes referred to singly as “Party” and collectively as “Parties”. 

WITNESSETH 
 WHEREAS, the
INSTITUTIONS are the sole owners of certain Licensed Rights (as later defined herein) associated with technology relating to unique chemical linkages in compounds that alter second messenger signaling (hereinafter defined as “Technology”)
and has the right to grant licenses under said Licensed Rights; and 
 WHEREAS, the INSTITUTIONS desire to have the Licensed Rights utilized
in the public interest and is willing to grant a license to its interest thereunder; and 
 WHEREAS, LICENSEE seeks to commercially develop
the Licensed Rights through a thorough, vigorous and diligent program of exploiting the Licensed Rights whereby public utilization shall result therefrom; 

WHEREAS, the Licensed Rights were developed, at least in part, by Dr. Thomas Tuschl, an employee of the Howard Hughes Medical Institute
(“HHMI”) at his laboratory at The Rockefeller University; 
 NOW, THEREFORE, in consideration of the premises and the mutual
covenants contained herein, the parties hereto agree as follows: 
 ARTICLE I 

DEFINITIONS 
 For the purpose of
this Agreement, the following words and phrases shall have the following meanings: 
 1.1 “Affiliate” as used herein in either
singular or plural means, with respect to a party, any corporation, company, partnership, joint venture or other entity, which directly or indirectly: (a) Controls, is Controlled by or is under common Control with the specified entity; or
(b) both (i) owns, is owned by, or is under common ownership with the specified entity, in whole or in part, and (ii) conducts business under a trade identifier of the specified entity, with the authorization of the specified entity.
For purposes of this definition, “Control” of an entity means the direct or indirect ownership or control of at least fifty percent (50%) of the right to direct or cause the direction of the policies and management of such person or
entity, whether by the ownership of 
  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -1- 

 
stock, by contract or otherwise. In any jurisdiction where 50% control is not permitted by applicable law, the “greater than 50%” threshold shall be deemed satisfied by the possession
of substantially the maximum percentage allowable in such jurisdiction. The term “control” wherever used in this Agreement shall mean ownership, directly or indirectly, of more than fifty percent (50%) of the equity capital. 

1.2 “Agreement” means this Exclusive License Agreement between the Parties effective on the Effective Date. 

1.3 “Confidential Information” shall mean all confidential and proprietary information disclosed by one Party to the other Party
regarding the Technology, including any uses, processes, methods, formulations, clinical data, test results, research and development plans, pricing policies, business plans, sales, information relating to customer identities, characteristics and
agreements, financial information and projections, work in progress, future development, marketing, and investors whether in oral, graphic, electronic or any other media or form. The Confidential Information of LICENSEE shall include the existence
and terms of this Agreement. “Confidential Information” shall not include information: (a) which is now, or becomes in the future, public knowledge other than through acts or omissions of receiving party; (b) which is lawfully
obtained by the receiving party without a confidentiality restriction and without breach of this Agreement from a source other than a party hereto; or (c) which the receiving party can demonstrate was independently developed by employees of the
receiving party having no knowledge of the Confidential Information. The Confidential Information of UB shall be deemed to include all related Confidential Information disclosed by the employees of PROvendis GmbH in connection with this Agreement.

 1.4 “Contract Quarter-Year” shall mean the three month periods ending on
March 31, June 30, September 30 and December 31 of each year. 
 1.5 “Field of Use” shall mean
therapeutic and/or prophylactic use in humans. 
 1.6 “First Commercial Sale” means the first commercial sale of a Licensed
Product in a country in the Territory, which product is sold as part of commercialization effort. Licensed Product provided for: (i) clinical study purposes; (ii) compassionate use; (iii) similar uses by a limited number to support
regulatory approval (provided that the Licensed Product is not otherwise generally available for purchase in such country); and (iv) early access programs; shall not constitute a First Commercial Sale. 

1.7 “Know-How” means the proprietary and confidential know-how, skills, data, techniques, knowledge, protocols, regulatory filings,
assays, results of experimentation and testing, inventions, methods and other information, whether or not patentable, existing prior to the Effective Date of this Agreement as described in Exhibit B and that are necessary for the commercial
exploitation of the Patent Rights. 
 1.8 “Licensed Rights” shall mean Know-How and Patent Rights. 

1.9 “Licensed Products” means any product or component (whether alone or in combination with other products or ingredients) thereof
(i) the making, using, selling or 
  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -2- 

 
importation of which is covered, in whole or in part, by a Valid Claim, or (ii) which is manufactured using Know-How. For purposes of clarity, Licensed Product refers only to a product that
incorporate INSTITUTIONS’ proprietary chemical linkages described in the Licensed Rights in LICENSEE’S compounds contained in Exhibit C. 

1.10 “Net Sales” means LICENSEE’S and its Sublicensees’ invoiced sales price for Licensed Products less the sum of the
following: a) discounts actually allowed and granted; b) credits, rebates, or allowances actually granted; c) freight out, postage, shipping and insurance charges; e) bad debts and uncollectible receivables; provided that, in any calendar year, such
deduction will not exceed [ * ] of the total billings for sales of Licensed Products sold in that year; and (f) any other deductions permitted under U.S. generally accepted accounting principles. 

No deductions shall be made for commissions paid to commercial sales force members whether they be with independent sales agencies or
regularly employed by LICENSEE and on its payroll, provided that LICENSEE shall not be responsible for paying royalty on any amounts paid or payable to wholesalers and distributors for the Licensed Product. 

Licensed Products shall be considered sold when billed and invoiced. 

Customary distribution of samples of Licensed Product by LICENSEE or Affiliates shall not be included in any calculation of Net Sales provided
that the total volume of samples of Licensed Products distributed is less than [ * ] of the total volume of Licensed Products sold. 

Net Sales of a Combination Product in a country shall be calculated in accordance with Section 5.1(b)(i). 

Net Sales shall not accrue in respect of Licensed Product used for charitable uses or Licensed Product used for development, community access
programs, and sampling. 
 1.11 “Other Consideration” shall mean any payments received by LICENSEE or its Affiliates from a
Sublicensee(s) to the extent attributable specifically to the grant of a Sublicense to the Patent Rights [ * ], but not including royalties; purchases of equity or debt except to the extent the purchase price is more than [ * ] of fair
market value. 
 1.12 “Patent Rights” shall mean rights in all of the following intellectual property owned by INSTITUTIONS: 

(a) the United States patent applications listed in Exhibit A; 

(b) any United States and foreign patents, utility models, inventors certificates, invention registrations, continuing applications,
divisional applications, substitutions, and equivalents thereof in any jurisdiction, that claim priority to the provisional applications listed in Exhibit A; 

(c) any United States and foreign patents issued from the applications listed in Exhibit A, and from divisionals and continuations of these
applications; 
  
 [*] = Certain confidential information contained in this document,
marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -3- 

 (d) continuation-in-part applications, and equivalents thereof in any jurisdiction anywhere in
the world, and any United States and foreign patents issued therefrom, in each case solely regarding claims in such filings that are entitled to the filing date of the patent applications in (a) and are directed to subject matter specifically
described in the applications in Exhibit A; and 
 (e) any reissues, re-examinations or extensions of patents described in (a), (b), or (c);
and any reissues, re-examinations or extensions of patents described in (d) solely regarding claims that are directed to subject matter specifically described in the applications listed in Exhibit A. 

1.13 “Royalty Term” shall mean with respect to a given country in the Territory, the period beginning on the First Commercial Sale
of Licensed Product in such country and ending on the later of: (a) expiration of the last Patent Right covering such Licensed Product in such country or (b) ten (10) years from the First Commercial Sale in such country. 

1.14 “Royalty Year” shall mean each twelve (12) month period commencing January 1 and ending December 31 during the
term of this Agreement. For the first year of this Agreement, the Royalty Year shall be the period of time between the signing of the Agreement and December 31. 

1.15 “Sublicense” means the license from LICENSEE to a non-affiliated third party some or all of the Licensed Rights. For clarity,
any licenses granted to a third party in order to enable LICENSEE or its Affiliates or a Sublicensee to develop or commercialize Licensed Product or to otherwise fulfill its obligations hereunder shall not be considered a Sublicense. Examples of the
foregoing shall include, without limitation, licenses to contract manufacturers and wholesalers and distributors but shall not include sublicenses of Licensed Rights from Licensee to a third party bona fide collaborator or third party bona fide
Licensed Product development and commercialization partner in exchange for a payment to LICENSEE or material Other Consideration. 
 1.16
“Sublicensee” means any business entity to which a Sublicense is granted under Section 3.1. 
 1.17 “Term” shall
mean the term of this Agreement which begins on the Effective Date and expires on the date of the expiration of the last Royalty Term for any Licensed Product, unless earlier terminated pursuant to the Article 16 of this Agreement. 

1.18 “Territory” shall mean worldwide. 

1.19 “Valid Claim” shall mean a claim of (i) an issued and unexpired patent included within the Patent Rights unless the claim
has been held unenforceable or invalid by the final, un-reversed, and un-appealable decision of a court or other government body of competent jurisdiction, has been irretrievably abandoned or disclaimed, or has otherwise been finally admitted or
determined to be invalid, unpatentable or unenforceable, whether through reissue, reexamination, disclaimer or otherwise, or (ii) a pending patent application within the Patent Rights to the extent the claim continues to be prosecuted in good
faith, but not to exceed [ * ] years. 
  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -4- 

 ARTICLE II 

GRANT 
 2.1 License Grant. Subject
to the terms of this Agreement, the INSTITUTIONS hereby grant to LICENSEE and its Affiliates (i) an exclusive worldwide royalty-bearing license under their interest in and to the Patent Rights and (ii) a non-exclusive worldwide
royalty-bearing license under the Know-How, with respect to clauses (i) and (ii), to make, have made, use, have used, sell, have sold, offer for sale, import, have imported, export, have exported, develop, have developed, commercialize and have
commercialized Licensed Products in the Field of Use (whether alone or in combination with other products or ingredients) throughout the Term hereof in the Territory. LICENSEE acknowledges that on the Effective Date there is not an issued Valid
Claim of the Patent Rights in every country in the Territory. 
 2.2 Notwithstanding any other provisions of this Agreement, the rights
granted herein are subject to the right of the INSTITUTIONS and their respective Affiliates to freely practice the Patent Rights and Know-How, provided that INSTITUTIONS will not grant to a commercial third party the same rights granted to LICENSEE
to the Patent Rights hereunder. The INSTITUTIONS also reserve the right to permit others at academic, government, and non-profit institutions to use the Licensed Rights for their own internal, non-commercial, and educational research purposes,
including teaching and patient care activities. All rights reserved to the United States Government and others under 35 USC §§200-212, as amended, shall remain and shall in no way be affected by this Agreement.  

2.3 INSTITUTIONS reserve all rights not expressly granted in the Agreement. The license granted hereunder to LICENSEE shall not be construed
to confer any rights upon LICENSEE by implication, estoppel or otherwise as to any technology not included in the Licensed Rights. 
 2.4
LICENSEE acknowledges that it has been informed that the Patent Rights and Know-How were developed, at least in part, by employees of HHMI and that HHMI has a fully paid-up, non-exclusive, irrevocable, worldwide license to exercise any intellectual
property rights with respect to the Patent Rights and Know-How for research purposes, but with no rights to assign or sublicense (the foregoing research license, the “HHMI License”). This Agreement is explicitly made subject to the HHMI
License. 
 2.5 LICENSEE acknowledges that it has been informed that the Patent Rights and Know-How were developed, at least in part, by
employees of UB and that UB has a fully paid-up, non-exclusive, irrevocable, worldwide license to exercise any intellectual property rights with respect to the Patent Rights and Know-How for research purposes, but with no rights to assign or
sublicense (the foregoing research license, the “UB License”). This Agreement is explicitly made subject to the UB License. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -5- 

 ARTICLE III 

SUBLICENSES 
 3.1 LICENSEE shall
have the unrestricted right to grant Sublicenses of its rights granted under this Agreement, subject to written notice, and a confidential copy of such Sublicense will be provided to INSTITUTIONS with any competitive information redacted unless the
redaction of such competitive information would prevent INSTITUTIONS from confirming LICENSEE’s compliance with this Agreement including without limitation LICENSEE’s compliance with any financial provisions. In addition, upon request of
an INSTITUTION and solely to permit INSTITUTION to confirm LICENSEE’s compliance with its obligations related to the Sublicense, LICENSEE will make available an unredacted copy of the document in a format in which further reproduction or
distribution is disabled, such as electronically through a data room and/or physically through a reading room. LICENSEE agrees that any Sublicenses granted by it shall provide that the obligations to INSTITUTIONS set forth in Articles 2, 4, 6, 7, 8,
9, 10, 12, 13, and 14 and section 18.12 of this Agreement shall be binding upon the Sublicensee as if it were a party to this Agreement. Each sublicensee must be subject to a written agreement that also contains obligations, terms and conditions in
favor of HHMI or the HHMI Indemnitees and, as applicable, that are substantially similar to those undertaken by LICENSEE in favor of HHMI or the HHMI Indemnitees, as applicable, under this Agreement and intended for the protection of the HHMI
Indemnitees, including, without limitation, the obligations, terms and conditions regarding indemnification, insurance and HHMI’s third party beneficiary status. If a material breach of any of the clauses of the forgoing provision is caused by
Sublicensee, INSTITUTIONS shall have the right to require LICENSEE to terminate the Sublicense unless the material breach is cured within sixty (60) days after LICENSEE provides written notice of such material breach to the Sublicensee,
provided that INSTITUTIONS agree that if Sublicensee disagrees that there has been a material breach of the Sublicense and implements dispute resolution on that matter, then the cure period shall be tolled during completion of the dispute resolution
process. 
 3.2 Any subcontractor engaged by LICENSEE to perform for LICENSEE any of its rights and obligations under this Agreement (a
“Third Party Subcontractor”) shall be party to a written agreement consistent with the terms and conditions of this Agreement, including without limitation, and as applicable, those provisions pertaining to confidentiality, intellectual
property rights, regulatory/safety matters, indemnification, insurance and HHMI’s third party beneficiary status. In all cases, LICENSEE remains fully responsible (i) for the performance of its obligations hereunder regardless of whether
such performance has been delegated to a Third Party Subcontractor, and (ii) for the actions and conduct of the Third Party Subcontractor in performance of LICENSEE’s obligations. 

ARTICLE IV 
 DILIGENCE 

4.1 LICENSEE and its Sublicensees shall use commercially reasonable efforts to develop and commercialize a Licensed Product. 

(a) Specifically, the LICENSEE will: 

(i) [ * ] within [ * ] of the Effective Date or pay [ * ]; 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -6- 

 (ii) [ * ] within [ * ] of the Effective Date or pay [ * ]
to postpone this diligence milestone and the remaining diligence milestones by [ * ] one time; 
 (iii) [ * ]
within [ * ] of the Effective Date; and 
 (iv) [ * ] within [ * ] of the Effective Date or pay [ *
] to postpone this diligence milestone by [ * ] one time; 
 (v) In the event LICENSEE fails to achieve any of the
milestones above or make the relevant payment, INSTITUTIONS may treat such failure as a material breach in accordance with Section 16.4, subject to the following. Notwithstanding the above, if INSTITUTIONS determine reasonably and in good faith
that the LICENSEE is using commercially reasonable efforts to develop and commercialize Licensed Product(s), INSTITUTIONS will agree to negotiate in good faith with LICENSEE to extend the diligence time requirements by a period not less than [ *
]. 
 LICENSEE shall not be responsible for, and the foregoing periods shall be extended to reflect, circumstances beyond the reasonable
control of the LICENSEE. Such circumstances may include technical difficulties or delays in preclinical or clinical studies or regulatory processes. 

(b) LICENSEE agrees to give INSTITUTIONS written notice and evidence within [ * ] days of the achievement of each of the milestones set
forth in Section 4.1(a) above. 
 (c) LICENSEE will have delivered to INSTITUTIONS prior to the execution of this Agreement, its
detailed business plan for the development of the Licensed Rights, substantially in the form attached hereto as Exhibit D. LICENSEE shall provide similar reports to INSTITUTIONS annually. 

(d) LICENSEE will be solely responsible, at LICENSEE’s sole cost and expense, for securing any federal (including FDA), state, or local
regulatory approval necessary for commercial sale of Licensed Products (“Regulatory Approval”). INSTITUTIONS will provide reasonable cooperation through providing LICENSEE, upon LICENSEE’s written request and in a timely fashion, with
all documentation and information reasonably necessary to secure such Regulatory Approval. LICENSEE shall advise INSTITUTIONS, through annual reports described in Section 4.1(c) above of its program of development for obtaining said approvals.

 4.2 If LICENSEE is the subject of an inquiry or inspection by a governmental authority or certification agency in relation to any
Licensed Product, LICENSEE will notify INSTITUTIONS as soon as reasonably possible and keep INSTITUTIONS reasonably apprised of the results of such inspection. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -7- 

 ARTICLE V 

PAYMENTS 
 5.1 INSTITUTIONS
acknowledge and agree that all payments to be made under or in connection with this Agreement shall be made to MSK on behalf of INSTITUTIONS, and LICENSEE does not have an obligation to make payments directly to any INSTITUTION other than MSK unless
specifically agreed to otherwise by all the Parties in writing. MSK agrees to share such payments with the other INSTITUTIONS as agreed in writing among them and LICENSEE is not responsible therefor. In partial consideration of its rights hereunder,
LICENSEE shall pay to MSK in the manner hereinafter provided, until the end of the Term: 
 (a) License Fee: LICENSEE shall pay to MSK a
license issue fee of Fifty Thousand US Dollars (US$50,000) within [ * ] days of execution of this Agreement. 
 (b) Royalties on
Licensed Products: 
 (x) LICENSEE shall pay to MSK a running royalty equal to [ * ] of the worldwide annual Net Sales of Licensed Products covered by
a Valid Claim during the Royalty Term. 
 (y) LICENSEE shall pay to MSK a running royalty equal to [ * ] of the worldwide annual Net Sale of Licensed
Products not covered by a Valid Claim during the Royalty Term. 
 (i) Such royalties shall be payable for each calendar
quarter and shall be due and payable to MSK within [ * ] days after the end of each such calendar quarter.If a Licensed Product is sold in combination with other services or products (“Combination Product”), Net Sales are determined
on a country-by-country basis by multiplying the Net Sales by the fraction A / (A + B) wherein “A” is the value of the Net Sales of the Licensed Product in a given country and “B” is the is the net sales of the other service(s)
or product(s) of the Combination Product when sold separately during the same calendar quarter in the same country. If there is no substantial data on separate pricing, then the Parties shall agree upon the appropriate allocation of value between
the products and services in the Combination Product, such agreement not to be unreasonably withheld. 
 (ii) Annual minimum
royalty payments: LICENSEE shall pay to MSK minimum annual royalties of: 
 (A) [ * ] on the [ * ]
anniversaries of the Effective Date; 
 (B) [ * ] on the [ * ] anniversaries of the Effective Date; 

(C) [ * ] commencing on the [ * ] anniversary of the Effective Date and due and payable on each subsequent
anniversary until the end of the Term. 
  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -8- 

 Such minimum royalty payments shall be prorated for the year of issuance. The minimum royalty
payments shall be credited against the earned royalty payments due and payable in respect of the same Royalty Year. 
 (iii)
No multiple royalties shall be payable by LICENSEE including without limitation because any Licensed Product, its manufacture, use, lease, sale, import or provision is or shall be covered by more than one of the Licensed Rights granted under this
Agreement. 
 (c) Milestones: 

Milestone payments are one time payments that LICENSEE will pay to MSK for each Licensed Product as follows: 

 

	 	(i)	[ * ] upon [ * ]; 

  

	 	(ii)	[ * ] upon [ * ]; 

  

	 	(iii)	[ * ] upon [ * ]; 

  

	 	(iv)	[ * ] upon [ * ]. 

  

	 	(v)	[ * ] upon [ * ]. 

 (d) Sharing of Other Consideration: Subject to subsection
(e) below, LICENSEE shall pay to MSK a portion of Other Consideration received from a Sublicensee based on the date of receipt as follows: 
  

	 	(i)	[ * ]: [ * ] 

  

	 	(ii)	[ * ]: [ * ] 

  

	 	(iii)	[ * ]: [ * ] 

  

	 	(iv)	[ * ]: [ * ] 

 (e) If consideration is received by LICENSEE for the sublicense or
other transfer of the licenses and rights granted to LICENSEE and the transaction giving rise to such consideration constitutes: 
  

	 	(i)	[ * ] due to MSK under this Agreement. 

  

	 	(ii)	[ * ] due to MSK under this Agreement. 

 Under no circumstances shall INSTITUTION’S share of Other
Consideration be less than [ * ]. Also, in no circumstances shall MSK’s percentage of Other Consideration be less than each other third party(ies) Other Consideration percentage. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -9- 

 5.2 Payment Terms: Payments shall be due and payable [ * ] days after they are due, paid
in United States dollars in New York, NY, or at such other place as MSK may reasonably designate consistent with the laws and regulations controlling in any foreign country, but not in any other currency. If any currency conversion shall be required
in connection with the payment of royalties hereunder, such conversion shall be made by using the exchange rate prevailing at the JP Morgan Chase Bank on the last business day of the Contract Quarter-Year reporting period to which such royalty
payments relate. The License Fee due under Section 5.1(a) above and the past patent costs in the amount of $100,254.19 due under Section 7.1 below shall be due and payable within [ * ] days after the Effective Date. 

5.3 INSTITUTIONS are not-for-profit, tax-exempt, academic and research medical centers. The LICENSEE agrees that if this Agreement is
subject to taxation by any governmental authority, the LICENSEE will cooperate with INSTITUTIONS in its efforts to pay only those taxes legally required by the relevant governmental authority. If any withholdings are to be withheld by the LICENSEE
on any payment(s) to be made to MSK pursuant to this Agreement, then the LICENSEE will timely inform MSK of the specific withholdings in order to allow MSK to seek exemption. To the extent available to LICENSEE and relevant to the calculation of
amounts due and payable under this Agreement, LICENSEE shall verify the related tax amount and payment, and shall provide: 

(i) copies of tax assessments from the requesting tax authority, evidencing the amount of the assessed tax that is to be
withheld, and the country and authority to whom it should be paid; 
 (ii) copies of tax receipts from, and tax declarations
filed with, the requesting taxing authority, evidencing that the required amount was paid to the appropriate country and authority; 

(iii) any other documentation to satisfy compliance with the LICENSEE’s royalty reporting obligations under this
Agreement; and 
 (iv) any other information MSK, or its auditors, may reasonably request regarding the payment of taxes.

 LICENSEE agrees to provide any translations of the foregoing to the extent the original is not in English and a translation was prepared by LICENSEE.

 5.4 In the event the royalties set forth in the Agreement are higher than the maximum royalties permitted by the law or regulations of a
particular country, then the royalty payable for sales in such country shall equal to the maximum permitted royalty under such law or regulations. Notice of such an event shall be provided to MSK. An authorized representative of the LICENSEE shall
notify MSK, in writing, within [ * ] days of discovering that such royalties are approaching or have reached the maximum amount, and shall provide MSK with written documentation regarding the laws or regulations establishing such maximum, and
a translation into English. 
 5.5 Interest: LICENSEE shall pay to MSK interest on any amounts not paid when due. Such interest will accrue
from the [ * ] day after the payment was due and payable at an annual 
  
 [*]
= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -10- 

 
rate of [ * ] or the highest interest rate permitted by law, whichever is lower. The interest payment will be due and payable on the first day of each calendar month after interest begins
to accrue, until full payment of all amounts due and payable MSK is made. MSK rights to receive such interest payments shall be in addition to any other rights and remedies available to MSK. 

ARTICLE VI 
 REPORTS AND RECORDS

 6.1 LICENSEE shall keep, and shall require its Affiliates and Sublicensees to keep, full, true and accurate books of account containing
all particulars that may be necessary for the purpose of showing the amounts payable to MSK hereunder. Said books and records shall include, but not be limited to: Invoice registers and original invoices, product sales analysis reports, accounting
general ledgers, sub-license and distributor agreements, price lists, product catalogs and marketing materials, audited financial statements and/or income tax returns, sales tax returns, inventory and production records and shipping documents. Said
books and records shall be maintained for a period of no less than [ * ] years following the period to which they pertain. Such records shall include original data files used to prepare the submitted royalty reports for the term of this
Agreement, and at least annually, MSK or their agents shall have the right once per year upon written notice to inspect such books and records for the purpose of verifying LICENSEE’s royalty statement or compliance in other respects with this
Agreement. Such inspections shall be during normal working hours of LICENSEE. Should such inspection lead to the discovery of an underpayment of greater than [ * ] of the amount owed for the relevant calendar year, LICENSEE agrees to pay all
costs for the inspection, in addition to repaying the underpayment with interest. 
 If the audit determines an error that is due to
misinterpretation of the license agreement language or if the error results from the application of an incorrect accounting or clerical methodology, LICENSEE shall be entitled to correct such errors without penalty. Any additional royalties due from
the correction of errors from the prior periods will not be subject to late payment interest as called for in Article 5 of the Agreement. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -11- 

 6.2 Commercialization Reports: LICENSEE, within [ * ] days of the end of each Contract
Quarter-Year beginning after First Commercial Sale of a Licensed Product, shall deliver to MSK true and accurate reports setting forth the Net Sales for the prior Contract Quarter-Year. The reports shall include at least the following information,
to be itemized per Licensed Product and/ or Licensed Service by country of sales origin: 
  

	 	(a)	Extended sales dollars; 

  

	 	(b)	Royalty rate; 

  

	 	(c)	Extended royalty dollars due; 

  

	 	(d)	the portion of Net Sales that was received from Sublicensees; and 

  

	 	(e)	any Other Consideration received in the prior quarter. 

 6.3 With each such report submitted,
LICENSEE shall pay to MSK the royalties due and payable under this Agreement. If no royalties shall be due, LICENSEE shall so report. In addition, LICENSEE shall also submit annually a report summarizing LICENSEE’s research, development,
commercialization and other business progress during the prior year that relates to Licensed Products, and its projections of activity anticipated for the next year. 

6.4 Milestone payments shall be reported and paid when due. 

6.5 LICENSEE agrees to forward to MSK a copy of all fully executed Sublicense agreements and any reports received by LICENSEE from its
sublicensees during the preceding Royalty Year (to the extent required under Section 3.1 hereof). 
 ARTICLE VII 

PATENT PROSECUTION 
 7.1 Patent
Cost Reimbursement. LICENSEE shall reimburse during the term of the Agreement reasonable out-of-pocket expenses borne by INSTITUTIONS for filing, prosecuting and maintaining Patent Rights through an independent third-party counsel of
INSTITUTIONS’ choice, reasonably acceptable to LICENSEE. LICENSEE shall reimburse INSTITUTIONS for all historic patent costs related to the Patent Rights within [ * ] days of the Effective Date. 

7.2 INSTITUTIONS shall diligently file, prosecute, protect, and maintain the Patent Rights in the United States and in such countries as are
determined by INSTITUTIONS and agreed to by LICENSEE or as may be designated by LICENSEE in a written notice to INSTITUTIONS within a reasonable time in advance of the required foreign filing dates, using independent third-party counsel. If LICENSEE
does not agree to bear the expense of filing or maintaining patent applications in any foreign countries in which INSTITUTIONS wish to obtain patent protection, then INSTITUTIONS may file and prosecute such applications at its own expense and any
license granted hereunder shall exclude such countries. If LICENSEE requests filings in additional countries or jurisdictions, INSTITUTIONS shall comply at LICENSEE’s cost. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -12- 

 7.3 LICENSEE shall have the opportunity to advise and cooperate with INSTITUTIONS in the
prosecution, filing and maintenance of such patents. INSTITUTIONS shall provide LICENSEE with copies of all relevant patent prosecution documentation so that LICENSEE may be informed and to give LICENSEE reasonable opportunity to advise INSTITUTIONS
on the continuing prosecution, and LICENSEE agrees to keep this documentation confidential. 
 7.4 Patent counsel remains counsel to
INSTITUTIONS with an appropriate contract (and shall not jointly represent LICENSEE unless mutually agreed to in writing by the Parties). 

7.5 The Parties agree that they share a common legal interest in obtaining valid, enforceable patents and that LICENSEE will maintain
confidential all information received pursuant to this Article 7. 
 7.6 In the event INSTITUTIONS license Patent Rights to third
party(ies), INSTITUTIONS shall notify LICENSEE and patent expenses described above shall be shared among the Patent Right licensees according to the rights granted to each licensee. 

ARTICLE VIII 
 INFRINGEMENT 

8.1 Monitoring. LICENSEE shall use commercially reasonable efforts to monitor third party infringement of the Patent Rights in the Field of
Use. LICENSEE shall keep INSTITUTIONS timely informed of any activities by LICENSEE in regard hereto 
 8.2 Actions. Each Party shall inform
the other promptly in writing of any alleged commercially material infringement of the Patent Rights by a third party, and of any available evidence thereof. This Section sets forth the parties’ right of enforcement and defense in relation to
the Patent Rights. 
 (a) First Right. LICENSEE (and its Sublicensees) shall have the first right, but not the obligation, to control the
conduct and resolution of any adversarial legal proceeding relating to the Patent Rights (including without limitation any declaratory judgment action, patent infringement action or opposition) during the Term and will be responsible for all
expenses related thereto. INSTITUTIONS shall join in any such action, at LICENSEE’s request and expense. 
 (b) Secondary Right. If
LICENSEE does not wish to exercise either of the foregoing rights in (a), LICENSEE shall provide INSTITUTIONS with written notice no later than [ * ] calendar days after receipt of notification of alleged infringement, that LICENSEE declines
such right, and after receiving such notice, INSTITUTIONS shall have the secondary right to undertake such infringement action or defend against such challenge and will in that case be responsible for all expenses related thereto. INSTITUTIONS are
not obligated to take part. 
 8.3 Cooperation. To the extent either Party (or its Sublicensees) conducts any legal proceedings in relation
to the enforcement or defense of Patent Rights in the Field of Use, it shall keep the other Party reasonably informed of such proceedings. The other Party shall cooperate in 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -13- 

 
all respects and, to the extent reasonably possible, have its employees testify when requested and make available relevant records, papers, information, samples, specimens, and the like at the
expense of the requesting party. Notwithstanding anything to the contrary: (a) in any action conducted by INSTITUTIONS, INSTITUTIONS may use the name of LICENSEE as party plaintiff, and LICENSEE will join any such action as may be requested by
INSTITUTIONS; (b) in any action conducted by LICENSEE, LICENSEE may affect joinder of INSTITUTIONS, if INSTITUTIONS are indispensable or necessary parties under the applicable law; and (c) no settlement, consent judgment or other voluntary
final disposition of any action by LICENSEE that admits or impairs the invalidity or unenforceability of the Patent Rights may be entered into without the prior written consent of INSTITUTIONS, which consent shall not unreasonably be withheld. 

8.4 Costs and Recoveries. All costs of any action by either Party to enforce, or to defend against a challenge to, the Patent Rights shall be
borne by such party, which shall keep any sums recovered or obtained in connection therewith (whether as damages, reasonable royalties, license fees, or otherwise in judgment or settlement derived therefrom), except that in the case of actions
commenced by LICENSEE, the excess of such recoveries after payment of reasonable costs and expenses shall be treated as Net Sales subject to INSTITUTIONS’ rights under this Agreement to collect royalties thereon. For the avoidance of doubt,
LICENSEE may not otherwise deduct, from Net Sales payable on such overage any portion of LICENSEE’S internal costs or expenses related to any investigation, enforcement, defense, judgment or settlement of any such actions. 

8.5 Third Party Patents. In the event LICENSEE is sued for patent infringement or, threatened with such suit, it shall promptly notify
INSTITUTIONS. If LICENSEE is permanently enjoined from exercising its license rights granted hereunder LICENSEE may terminate this Agreement upon [ * ] days prior written notice to INSTITUTIONS. In any such action, LICENSEE shall be fully
responsible for all its costs, including expenses, judgments and settlements. 
 8.6 Patent Challenges by LICENSEE. LICENSEE will provide
written notice to INSTITUTIONS at least [ * ] months prior to LICENSEE or any of its Affiliates bringing any legal proceeding to challenge the validity or enforceability any claim included in the Patent Rights (a “Patent
Challenge”), including: (a) stating the basis for such Patent Challenge; and (b) providing a copy of all relevant prior art or other materials used as the basis for such Patent Challenge. In the event that LICENSEE brings a Patent
Challenge: (i) INSTITUTIONS may at any time thereafter terminate this Agreement upon written notice to LICENSEE; (ii) during pendency of the Patent Challenge, all license fees, milestone payments and royalties due under this Agreement will
be doubled; and (iii) in the event of an unsuccessful Patent Challenge by LICENSEE, (A) LICENSEE shall reimburse INSTITUTIONS for all reasonable costs and attorney fees that INSTITUTIONS incurs in connection with such Patent Challenge, and
(B) starting on the date (if at all) that the Patent Challenge is determined to be Unsuccessful, all license fees, milestone payments and royalty rates due as per this Agreement will be trebled. As used herein, “Unsuccessful” means
that, upon the conclusion of the action before the court or other governmental authority in which the Patent Challenge was brought, LICENSEE failed to obtain a judgment that all of the patent claims within the Patent Challenge were invalid or
unenforceable. 
  
 [*] = Certain confidential information contained in this
document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -14- 

 ARTICLE IX 

CONFIDENTIALITY 
 Each Party
agrees that Confidential Information of the other Party disclosed to it or to its employees under this Agreement shall for [ * ] years after the Term: 

(a) be used only in connection with the legitimate purposes of this Agreement; 

(b) be disclosed only to those who have a need to know it in connection with the Agreement; and 

(c) be safeguarded with the same care normally afforded confidential information in the possession, custody or control of the party holding
the Confidential Information but no less than reasonable. 
 (d) not be disclosed, divulged or otherwise communicated except with the
express written consent of the disclosing party. 
 The foregoing shall not apply when, after and to the extent the Confidential Information
disclosed: 
 (i) can be demonstrated to have been in the public domain prior to the date of the disclosure; or 

(ii) enters the public domain through no fault of the receiving party; or 

(iii) was already known to the receiving party at the time of disclosure as evidenced by written records in the possession of
the receiving party prior to such time; or 
 (iv) was subsequently received by the receiving party in good faith from a
third party without breaching any confidential obligation between the third party and the disclosing party; or 
 (v) was
independently developed, as established by tangible evidence, by the receiving party without reference to information or material provided by the disclosing party; or 

(vi) is required to be disclosed for minimal compliance with court orders, statutes or regulations or INSTITUTIONS’ audits
for compliance with such regulatory requirements, provided that prior to any such disclosure to the extent reasonably practicable, the party from whom disclosure is sought shall promptly notify the other party and shall afford such other party the
opportunity to challenge or otherwise lawfully seek limits upon such disclosure of Confidential Information. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -15- 

 ARTICLE X 

INDEMNIFICATION, PRODUCT LIABILITY 

10.1 LICENSEE will indemnify, defend and hold harmless (and cause its sublicensees to so indemnify, defer and hold harmless) INSTITUTIONS and
their respective trustees, directors, officers, medical and professional staff, employees, students, and agents and their respective successors, heirs, and assigns (each an “Indemnitee”), against all third party claims and expenses
(including legal expenses and reasonable attorney’s fees) arising out of the death of or injury to any person or persons, or out of any damage to property, against any infringement or misappropriation of intellectual property and against any
other claim, proceeding, demand, expense and liability of any kind whatsoever resulting from the production, manufacture, sale, use, lease, consumption, or advertisement of Licensed Products hereunder or from a breach by LICENSEE of any of its
representations, warranties or obligations under this Agreement, provided however, that LICENSEE will not be obligated to indemnify, defend and hold harmless any Indemnitee against any claim, proceeding, demand, expense, or liability to the extent
it arises out of, results from, or is increased by (a) the material breach of this Agreement by INSTITUTIONS, or (b) INSTITUTIONS’ gross negligence or willful misconduct. The Indemnitee will promptly give notice to LICENSEE of any
claims or proceedings which might be covered by this Section 10.1 and LICENSEE will have the right to defend the same, including selection of counsel and control of the proceedings; provided that LICENSEE will not, without the written consent
of the Indemnitee, settle or consent to the entry of any judgment with respect to such third party claims (i) that does not release the Indemnitee from all liability with respect to such third party claim, or (ii) which may materially
adversely affect the Indemnitee or under which the Indemnitee would incur any obligation or liability, other than one as to which LICENSEE has an indemnity obligation hereunder. INSTITUTIONS agree to cooperate and provide reasonable assistance to
such defense at LICENSEE’s expense. INSTITUTIONS at all times reserve the right to select and retain counsel of its own at its own expense to defend INSTITUTIONS’s interests. 

10.2 For the term of this Agreement, upon the commencement of clinical use, production, sale, or transfer, whichever occurs first, of any
Licensed Product, LICENSEE shall obtain and carry in full force and effect general liability insurance that shall protect LICENSEE, INSTITUTIONS, and HHMI in regard to events covered by Section 10.1 above and Section 10.4 below. Such
insurance shall be written by a reputable insurance company, shall list INSTITUTIONS and HHMI as an additional named insured thereunder, shall be endorsed to include liability coverage, and shall provide [ * ] days’ prior notice to
INSTITUTIONS prior to any cancellation or material change that would result in LICENSEE’s coverage being less than the coverage required by this provision. The limits of such insurance shall not be less than two million dollars ($2,000,000) per
occurrence with an annual aggregate of five million dollars ($5,000,000) for personal injury, death or property damage. LICENSEE shall provide INSTITUTIONS with Certificates of Insurance evidencing the same and provide INSTITUTIONS with prior
written notice of any material change in or cancellation of such insurance. 
 10.3 This Agreement and the licenses granted herein shall
immediately and automatically terminate without notice in the event LICENSEE or its Sublicensees or other party acting under authority of LICENSEE, fails to obtain the insurance required under Section 10.2, or if the insurance lapses or is
cancelled. A termination occurring under this paragraph shall occur 
  
 [*] =
Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -16- 

 
and become effective at the time such insurance coverage ends or becomes required and is not obtained, and LICENSEE or its Sublicensees shall then have no right to complete production and sale of
Licensed Products. Nothing herein shall be construed to release either party from any obligation that matured prior to the effective date of such termination. Notwithstanding the foregoing, in the [ * ] month period subsequent to the date of
such an automatic termination of this Agreement by operation of this paragraph, to the extent that such rights are still available for licensing, LICENSEE shall have the right to reinstate the effectiveness of this Agreement by obtaining the
required insurance, whereupon this Agreement shall automatically become effective as of the date of reinstatement of said insurance, and shall remain in full force and effect without any further action of the parties. 

10.4 HHMI and its trustees, officers, employees, and agents (collectively, “HHMI Indemnitees”), will be indemnified, defended by
counsel acceptable to HHMI, and held harmless by LICENSEE from and against any liability, cost, expense, damage, deficiency, loss, or obligation, of any kind or nature (including, without limitation, reasonable attorneys’ fees and other costs
and expenses of defense) based upon, arising out of, or otherwise relating to any third-party claim (collectively, “Claims”), based upon, arising out of, or otherwise relating to this Agreement or any sublicense, including without
limitation any cause of action relating to product liability. The previous sentence will not apply to any Claim that is determined with finality by a court of competent jurisdiction to result solely from the gross negligence or willful misconduct of
an HHMI Indemnitee. Notwithstanding any other provision of this Agreement, Company’s obligation to defend, indemnify and hold harmless the HHMI Indemnitees under this paragraph will not be subject to any limitation or exclusion of liability or
damages or otherwise limited in any way. 
 ARTICLE XI 

REPRESENTATIONS, WARRANTIES AND DISCLAIMERS 

11.1 Representations and Warranties of LICENSEE 

(a) LICENSEE hereby represents and warrants to INSTITUTIONS that as of the Effective Date, to its knowledge, the execution and performance of
LICENSEE’s obligations under this Agreement does not conflict with, cause a default under, or violate any existing contractual obligation that may be owed by LICENSEE to any third party. 

(b) LICENSEE hereby represents, warrants and covenants to INSTITUTIONS that all Licensed Products produced under the licenses granted herein
will be manufactured in all material respects in accordance with applicable federal, state and local laws, rules and regulations, including, without limitation, in all material respects in accordance with all applicable rules and regulations of the
FDA. 
 (c) LICENSEE hereby represents and warrants to INSTITUTIONS that LICENSEE is a corporation duly organized, validly existing and in
good standing and has all requisite corporate power and authority to execute and deliver this agreement. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -17- 

 11.2 Representations and Warranties of INSTITUTIONS 

(a) INSTITUTIONS hereby represent and warrant to LICENSEE that to the best of the INSTITUTIONS’ knowledge, they are the sole owners of the
Patent Rights and, as of the Effective Date, to the best of INSTITUTIONS knowledge, there is no pending or threatened infringement claim related to any of the Patent Rights granted hereunder. INSTITUTIONS have the right to grant LICENSEE all the
rights granted hereunder and have paid, and will pay, in full any amounts due to any relevant inventors in consideration of the PATENT RIGHTS, including any required to be paid under applicable law. 

11.3 Disclaimer. 
 EXCEPT AS
OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, INSTITUTIONS MAKE NO REPRESENTATIONS, NO WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, MERCHANTABILITY, VALIDITY OF LICENSED
RIGHTS, CLAIMS ISSUED OR PENDING OR THAT THE MANUFACTURE, SALE OR USE OF THE LICENSED PRODUCTS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY CONSEQUENTIAL,
INDIRECT, SPECIAL, INCIDENTAL, OR PUNITIVE DAMAGES ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, INCLUDING BUT NOT LIMITED TO LOSS OF ANTICIPATED PROFIT, FROM ITS PERFORMANCE OR NONPERFORMANCE OF ITS OBLIGATIONS UNDER THIS AGREEMENT. 

ARTICLE XII 
 EXPORT CONTROLS 

It is understood that INSTITUTIONS are subject to United States laws and regulations controlling the export of technical data, computer
software, laboratory prototypes and other commodities (including the Arms Export Control Act, as amended and the Export Administration Act of 1979), and that its obligations hereunder are contingent on compliance with applicable United States export
laws and regulations. The transfer of certain technical data and commodities may require a license from the cognizant agency of the United States Government and/or written assurances by LICENSEE that LICENSEE shall not export data or commodities to
certain foreign countries without prior approval of such agency. INSTITUTIONS neither represent that a license shall not be required nor that, if required, it shall be issued. 

ARTICLE XIII 
 NON-USE OF NAMES

 Neither Party shall use the name of the other Party, nor of any of their employees, nor any adaptation thereof, in any press release,
advertising, promotional or sales literature without prior written consent obtained from the other Party in each case. During and after the term of this Agreement, neither Party shall utilize or register any trademark, service mark, tradename, or
other trade identifier of the other Party, or that contains (in whole or in part) or is confusingly 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -18- 

 
similar to the foregoing, or is a translation of any of the foregoing, without the prior express written consent of the other Party. Notwithstanding the above, each Party may freely disclose in
the ordinary course of business (but not in a press release, except with prior approval) that it has entered into this Agreement. LICENSEE acknowledges that under HHMI policy, LICENSEE may not use the name of HHMI or of any HHMI employee (including
Dr. Tuschl) in a manner that reasonably could constitute an endorsement of a commercial product or service; but that use for other purposes, even if commercially motivated, is permitted provided that (1) the use is limited to accurately
reporting factual events or occurrences, and (2) any reference to the name of HHMI or any HHMI employees in press releases or similar materials intended for public release is approved by HHMI in advance. 

ARTICLE XIV 
 PUBLICATION 

LICENSEE recognizes and accepts that under INSTITUTIONS’ mission as academic medical centers, INSTITUTIONS and their investigators must
have a meaningful right to publish without LICENSEE’s approval or editorial control. INSTITUTIONS reserve the right to publish the scientific findings from research related to Licensed Rights. 

ARTICLE XV 
 ASSIGNMENT 

No party may assign or delegate any or all of its rights or obligations under this Agreement, or transfer this Agreement, without the prior
written consent of the other party, except that (a) either party shall have the right to assign any of its rights, delegate any of its obligations, or transfer this Agreement without such consent (i) to an Affiliate or (ii) as part of
a merger or acquisition or other transfer of all or substantially all of the assets of its business to which this Agreement pertains, and (b) INSTITUTIONS may without consent of LICENSEE freely assign all or any portion of the payments due
under this Agreement to a Third Party. Additionally, LICENSEE shall, on written prior consent of INSTITUTIONS (such consent not to be unreasonably withheld or delayed), be permitted to assign this Agreement in connection with the sale or transfer of
a limited portion of its business to which this Agreement pertains. Any assignment, delegation or transfer by any party without the consent of the other party shall be void and of no effect. 

ARTICLE XVI 
 TERMINATION 

16.1 Term. This Agreement commences on the Effective Date and shall remain in effect, until the end of the Royalty Term in all countries in
the Territory, as provided in Section 1.13 unless sooner terminated in accordance with the provisions herein. After expiration of this Agreement or the valid termination of this Agreement by LICENSEE pursuant to Section 16.5, the licenses
granted to LICENSEE hereunder shall survive and are hereby fully paid. 
 16.2 Bankruptcy or Cessation/Enjoinder of Business. INSTITUTIONS
may terminate this Agreement upon written notice to LICENSEE if: (a) a petition in bankruptcy is filed against LICENSEE and is consented to, acquiesced in or remains undismissed for sixty (60) days; (b)

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -19- 

 
LICENSEE makes a general assignment for the benefit of creditors, or a receiver is appointed for LICENSEE, and LICENSEE does not return to solvency before the expiration of a thirty (30) day
period; (c) LICENSEE ceases to do business; or (d) if the enactment of any law, decree, or regulation, or the issuance of any order (including, but not limited to, an injunction), by any governmental authority renders it impracticable or
impossible for LICENSEE to perform any of its obligations hereunder. 
 16.3 Nonpayment. If LICENSEE fails to pay INSTITUTIONS fees,
royalties, ongoing patent expenses or other amounts payable hereunder, and, following receipt of notice from INSTITUTIONS of such failure, such payments remain past due for more than [*] days after the date due and payable, and LICENSEE fails to pay
any amounts [*], INSTITUTIONS shall have the right to terminate this Agreement on [*] days’ prior written notice, unless LICENSEE pays to INSTITUTIONS within the [*] day notice period, all fees, royalties and patent expenses, together with any
interest due and payable thereon, [*]. 
 16.4 Breach. In addition to any other termination right specified in this Agreement, either party
may terminate this Agreement upon ninety (90) days’ written notice (specifying the breach to be cured and demanding it be cured) to the other party, if such other party materially breaches a provision of this Agreement, unless LICENSEE
cures any such breach prior to the expiration of the ninety (90) day period; or 
 16.5 Termination by LICENSEE. LICENSEE may terminate
this Agreement, in whole or in part, without cause on thirty (30) days’ notice to INSTITUTIONS. 
 16.6 Product Sell Off. In the
event of termination of this Agreement other than by INSTITUTIONS pursuant to Section 16.4, LICENSEE and its Sublicensees shall have the right for [ * ] months thereafter to dispose of all Licensed Products then in its inventory,
contingent upon LICENSEE: (a) providing to INSTITUTIONS an inventory identifying the volumes of Licensed Products on hand with LICENSEE that were manufactured or in process prior to the termination date, certified and signed by an officer of
the LICENSEE; and (b) continuing to submit all reports and make all payments (including, without limitation, royalties) that would have been required in accordance with this Agreement, if this Agreement had not terminated. 

16.7 [*]. The Parties shall negotiate all matters of joint concern in good faith, with the intention of resolving issues between them in a
mutually satisfactory manner. If a disagreement between the Parties cannot be resolved through informal discussions, it shall be deemed a “Dispute” upon one party (the “Declaring Party”) declaring, by the delivery of a written
notice (the “Notice”) to the other party, that a Dispute exists. The Notice shall specify the nature and cause of the Dispute and the action that the Declaring Party deems necessary to resolve the Dispute. Following receipt of the Notice,
the parties shall use good faith efforts to resolve the Dispute, including making personnel with appropriate decision-making authority available to the other Party to discuss resolution of the Dispute. If a Dispute is not resolved within [ *
] days of the date of the Notice, then the Declaring Party and the other Party shall resolve the Dispute in accordance with the [*] procedures below. The Parties agree that [*]. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -20- 

 16.8 Effect on Sublicensees. All sublicenses, and rights of Affiliates and Sublicensees, will
terminate as of the effective date of termination of this Agreement, provided, however, that if at the effective date of termination any Sublicensee is in good standing with regard to its obligations under its Sublicense and agrees to assume the
applicable obligations of LICENSEE hereunder, then, at the request of the Sublicensee, such Sublicense shall survive such termination or expiration of this Agreement and be assigned to INSTITUTIONS; provided, in such case the obligations of
INSTITUTIONS to Sublicensee shall not exceed the obligations of INSTITUTIONS to LICENSEE under the Agreement and obligations of Sublicensee to INSTITUTIONS shall not exceed the obligations of LICENSEE to INSTITUTIONS under the Agreement. 

16.9 Survival. Upon any expiration or termination of this Agreement, the following shall survive: 

(a) any provision expressly indicated to survive, such survival to extend for the period indicated or indefinitely, or if no survival period
is indicated; 
 (b) any liability which any Party has accrued prior to expiration or termination; 

(c) LICENSEE’s reporting and payment obligations for activities occurring prior to expiration or termination or after termination); and

 (d) ARTICLE 1 (entitled Definitions), ARTICLE 9 (entitled Confidentiality), ARTICLE 10 (entitled Indemnification, Product Liability),
ARTICLE 11 (entitled Representation, Warranties and Disclaimers), ARTICLE 13 (entitled Non-Use of Names), ARTICLE 17 (entitled Notices and Other Communications), and ARTICLE 18 (entitled Miscellaneous Provisions) and Sections 11.3 (entitled
Disclaimer), 16.8 (entitled Effect on Sublicensees), 16.9 (entitled Survival), and 18.12 (entitled HHMI Third-Party Beneficiary). 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -21- 

 ARTICLE XVII 

NOTICES AND OTHER COMMUNICATIONS 

Except for payments, each notice or other communication pursuant to this Agreement shall be sufficiently made or given when delivered by
courier or other means providing proof of delivery to such party at its address below or as it shall designate by written notice given to the other party: 

In the case of MSK: 
 Memorial
Sloan Kettering Cancer Center 
 Office of Technology Development 

If by mail: 
 1275 York Ave., Box
524 
 New York, NY 10065 
 If
by courier: 
 600 Third Avenue, 16th floor 

New York, NY 10016 
 Attn: Vice
President, Technology Development 
 Tel: [ * ] (not for notice) 

Fax: [ * ] (not for notice) 

With copies to: 
 Memorial Sloan
Kettering Cancer Center 
 Office of General Counsel 

If by mail: 
 1275 York Ave. 

New York, NY 10065 
 If by
courier: 
 1275 York Ave. 
 New
York, NY 10065 
 Attn: General Counsel 

Tel: [ * ] (not for notice) 

Fax: [ * ] (not for notice) 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -22- 

 In the case of LICENSEE: 

Aduro Biotech, Inc. 
 626
Bancroft Way, 3C 
 Berkeley, California 94710 

Attention: CEO and President 

ARTICLE XVIII 
 MISCELLANEOUS
PROVISIONS 
 18.1 Governing Law; Disputes. This Agreement shall be construed, governed, interpreted and applied in accordance with the laws
of the State of New York, without giving effect to any choice/conflict of law principles, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent was filed or
granted. Disputes arising from this Agreement shall be resolved as set forth in Section 16.7. 
 18.2 Assignment. No party may assign
or delegate any or all of its rights or obligations under this Agreement, or transfer this Agreement, without the prior written consent of the other party, except that (a) either party shall have the right to assign any of its rights, delegate
any of its obligations, or transfer this Agreement without such consent (i) to an Affiliate or (ii) as part of a merger or acquisition or other transfer of all or substantially all of the assets of its business to which this Agreement
pertains, and (b) INSTITUTIONS may without consent of LICENSEE freely assign all or any portion of the payments due under this Agreement to a Third Party. Any assignment, delegation or transfer by any party without the consent of the other
party shall be void and of no effect. 
 18.3 Severability. Except to the extent a provision is stated to be essential, or otherwise to the
contrary, the provisions of this Agreement are severable, and in the event that any provisions of this Agreement shall be determined to be invalid or unenforceable under any controlling body of the law, such invalidity or unenforceability shall not
in any way affect the validity or enforceability of the remaining provisions hereof. 
 18.4 Marking. LICENSEE agrees to legibly mark the
Licensed Products (and packaging, marketing materials, package inserts, patient information leaflets, and other documentation therefore) sold in the United States with all applicable United States patent numbers, and other notices relating to
INSTITUTIONS’ Patent Rights, such markings and notices to be in accordance with any written guidelines that may be provided by INSTITUTIONS from time to time. All Licensed Products shipped to or sold in other countries shall be marked in such a
manner as to conform to the patent laws and practice of the country of manufacture or sale. In connection with such patent marking, LICENSEE shall also include a statement that the Licensed Product is made under license from INSTITUTIONS. 

18.5 Waiver. The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement
shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -23- 

 18.6 Counterparts. This Agreement may be executed in any number of counterparts and each of such
counterparts shall for all purposes be an original and all such counterparts shall together constitute but one and the same agreement. 

18.7 Force Majeure. Neither party shall lose any rights hereunder or be liable to the other party for damages or losses (except for payment
obligations) on account of failure of performance by the defaulting party to the extent such the failure arises from circumstances outside the reasonable control of the party, which may include war, strike, fire, act of God, earthquake, flood,
lockout, embargo, governmental or regulatory acts or orders or restrictions (except if imposed due to or resulting from the party’s violation of law or regulations), market disruptions, recession, depression, monetary controls, and failure of
suppliers; provided, however, that the affected party is using reasonable efforts to bring about an end to the force majeure or to mitigate its effects, to the extent such efforts are possible and commercially reasonable. In connection therewith, in
no event shall a party be required to settle any labor dispute or disturbance. 
 18.8 Further Assurances. At any time or from time to time
on and after the date of this Agreement, INSTITUTIONS shall at the written request of LICENSEE execute, and deliver or cause to be delivered, all such consents, documents or further instruments required by law to register or confirm the licenses
granted in this Agreement. 
 18.9 Entire Agreement. This Agreement, including its attachments and exhibits (which attachments and exhibits
are incorporated herein by reference), constitutes the entire understanding among and between the parties with respect to the subject matter hereof, and supersedes all prior agreements and communications, whether written, oral or otherwise. This
Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by the parties to this Agreement. 

18.10 Relationship between the Parties. The relationship between the parties under this Agreement is that of independent contractors. Nothing
contained in this Agreement shall be construed to create a partnership, joint venture or agency relationship between any of the parties. No party is a legal representative of any other party, and no party can assume or create any obligation,
liability, representation, warranty or guarantee, express or implied, on behalf of another party for any purpose whatsoever. 
 18.11
Construction and Interpretation. Words (including defined terms) denoting the singular shall include the plural and vice versa. The words “hereof”, “herein”, “hereunder” and words of the like import when used in this
Agreement shall refer to this Agreement as a whole, and not to any particular provision of this Agreement. The term “include” (and any variant thereof), and the giving of examples, shall not be construed as terms of limitation unless
expressly indicated by the context in which they is used. The headings in this Agreement shall not affect its interpretation. Except as expressly provided herein, the rights and remedies herein provided shall be cumulative and not exclusive of any
other rights or remedies provided by law or otherwise. Each of the parties has had an opportunity to consult with counsel of its choice. Each provision of this Agreement shall be construed without regard to the principle of contra proferentum. If
any provision of this Agreement is held to be invalid or unenforceable the validity of the remaining 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -24- 

 
provisions shall not be affected. The parties shall replace the invalid or unenforceable provision by a valid and enforceable provision closest to the intention of the parties when signing this
Agreement. This Agreement was negotiated, and shall be construed and interpreted, exclusively in the English language. 
 18.12 HHMI
Third-Party Beneficiary. HHMI is not a party to this Agreement and has no liability to any licensee, sublicensee, or user of anything covered by this Agreement, but HHMI is an intended third-party beneficiary of this Agreement and certain of its
provisions are for the benefit of HHMI and are enforceable by HHMI in its own name. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -25- 

 IN WITNESS WHEREOF, authorized representatives of the parties have signed and dated this
Agreement below. 
  

									
	LICENSEE				MEMORIAL SLOAN KETTERING CANCER CENTER
					
	By:		 /s/ Gregory W. Schafer
				By:		 /s/ Gregory Raskin

	Name:		Gregory W. Schafer				Name:		Gregory Raskin, MD
	Title:		COO				Title:		Vice President
									Technology Development
					
	Date:		December 18, 2014				Date:		December 18, 2014

  

			
	THE ROCKEFELLER UNIVERSITY
		
	By:		 /s/ Kathleen A. Deni

	Name:		Kathleen A. Denis, Ph.D.
	Title:		Associate VP, Technology Transfer
		
	Date:		December 19, 2014
	
	RUTGERS UNIVERSITY
		
	By:		 /s/ S. David Kimball

	Name:		S. David Kimball
	Title:		Associate Vice President, Research Commercialization
		
	Date:		12/22, 2014
	
	THE UNIVERSITY OF BONN
		
	By:		 /s/ Rüdiger Mull

	Name:		Rüdiger Mull
	Title:		Rheinische
			Friedrich-Wilhelms-Universität
			Der Kanzler
		
	Date:		December 19, 2014

  
 [*] = Certain confidential information contained in
this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -26- 

 Exhibit A 

Patent Rights 
 [ * ] 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 A-1 

 Exhibit B 

“Know-How” Related to Licensed Cyclic Dinucleotide (CDN) Structures 

[ * ] 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 C-1 

 Exhibit C 

Aduro Proprietary Cyclic Dinucleotide Structures 

[ * ] 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 C-2 

 Exhibit D 

Development Plan 
 <8
pages omitted> 
 [ * ] 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 C-3EX-10.29

 [*] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

Exhibit 10.29 

MANUFACTURING SERVICES AGREEMENT 

This Manufacturing Services Agreement (this “Agreement”) is made as of August 6, 2013, (the “Effective
Date”) between Lonza Walkersville, Inc., a Delaware corporation having its principal place of business at 8830 Biggs Ford Road, Walkersville, Maryland 21793 (“LWI”), and Aduro BioTech, Inc., a Delaware
corporation located at 626 Bancroft Way, 3C, Berkeley, CA 94710-2224 (“CLIENT”) (each of LWI and CLIENT, a “Party” and, collectively, the “Parties”). 

RECITALS 
 A. LWI operates
a multi-client production facility located at 8830 Biggs Ford Road, Walkersville, Maryland 21793 (the “Facility”). 
 B.
CLIENT desires to have LWI produce a product containing human cells and intended for therapeutic use in humans, and LWI desires to produce such product. 

C. CLIENT desires to have LWI conduct work according to individual Statement of Work, as further defined in Section 1.37 below. 

NOW, THEREFORE, in consideration of the foregoing and the mutual promises and covenants hereinafter set forth, and other good and valuable
consideration, the receipt and sufficient of which is acknowledged by the Parties, LWI and CLIENT hereby agree as follows. 
 AGREEMENT

  

	1.	DEFINITIONS 

 When used in this Agreement, capitalized terms will have the
meanings as defined below and throughout the Agreement. Unless the context indicates otherwise, the singular will include the plural and the plural will include the singular. 

1.1 “Acceptance Period” shall have the meaning set forth in Section 5.2.2. 

1.2 “Affiliate” means, with respect to either Party, any other corporation or business entity that directly, or indirectly
through one or more intermediaries, controls, is controlled by or is under common control with such Party. For purposes of this definition, the term “control” and, with correlative meanings, the terms “controlled by” and
“under common control with” means direct or indirect ownership of more than fifty percent (50%) of the securities or other ownership interests representing the equity voting stock or general partnership or membership interest of such
entity or the power to direct or cause the direction of the management or policies of such entity, whether through the ownership of voting securities, by contract, or otherwise. 

 1.3 “Applicable Laws” means all applicable laws, statutes, regulations,
guidelines, guidance and ordinances of the relevant regulatory authorities, including cGMP, in or of the United States and the European Union if agreed in the relevant Statement of Work. 

1.4 “Batch” means a specific quantity of Product that is intended to have uniform character and quality, within specified
limits, and is produced according to a single manufacturing order during the same cycle of manufacture. 
 1.5 “Batch
Documentation” has the meaning set forth in Section 5.2.1. 
 1.6 “Batch Record” means the production record
pertaining to a Batch. 
 1.7 “cGMP” means, as amended from time to time, the regulatory requirements for current good
manufacturing practices promulgated by the FDA under 21 CFR Parts 210 and 211, and, as applicable, Guide to Good Manufacturing Practices for Medicinal Products as promulgated under European Directive 91/356/EEC. 

1.8 “Change Order” has the meaning set forth in Section 2.2. 

1.9 “CLIENT Development Materials” has the meaning set forth in Section 2.3. 

1.10 “CLIENT New IP” has the meaning set forth in Section 11.1.3. 

1.11 “CLIENT Personnel” has the meaning set forth in Section 4.6.1. 

1.12 “CLIENT Process” has the meaning set forth in Section 11.1.2. 

1.13 “CLIENT Technology Transfer” means the transfer of documentation, specifications, and production process by CLIENT to
LWI for the development of the Master Production Record for the manufacturing of the Product specifically for the CLIENT. 
 1.14
“Confidential Information” has the meaning set forth in Section 10.1. 
 1.15 “Disapproval Notice”
has the meaning set forth in Section 5.2.3. 
 1.16 “Delivery Period” has the meaning set forth in Section 4.3.

 1.17 “Draft Plan” has the meaning set forth in Section 4.1. 

1.18 “FDA” means the U.S. Food and Drug Administration, and any successor agency thereof. 

1.19 “Intellectual Property” means, with respect to a Party, all its worldwide rights to patents, copyrights, trade secrets,
know-how and all other intellectual property rights, including all applications and registrations with respect thereto, but excluding all trademarks, trade names, service marks, logos and other corporate identifiers. 

1.20 “Losses” has the meaning set forth in Section 15.1. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -2- 

 1.21 “LWI Intellectual Property” means the proprietary Intellectual Property of
LWI, including, but without limitation, LWI New IP and LWI Operating Documents. 
 1.22 “LWI New IP” has the meaning set
forth in Section 11.1.4. 
 1.23 “LWI Operating Documents” means LWI’s proprietary standard operating procedures,
standard manufacturing procedures, raw material specifications, protocols, validation documentation, and supporting documentation used by LWI, such as environmental monitoring, for operation and maintenance of the Facility and LWI equipment used in
the process of producing the Product, excluding any of the foregoing that are unique to the manufacture of Product. 
 1.24 “LWI
Parties” has the meaning set forth in Section 15.2. 
 1.25 “Master Production Record” means the
documentation developed by LWI that contains a detailed description of the Process and any other instructions to be followed by a party in the production of the Product, which record meets the reasonable requirements of CLIENT and is approved by the
CLIENT in writing. 
 1.26 “Materials” means all raw materials and supplies, including without limitation cell lines, to be
used in the production of a Product. 
 1.27 “Process” means the manufacturing process for the Product developed by LWI
pursuant to the terms of this Agreement. 
 1.28 “Product” has the meaning set forth in a Statement of Work. 

1.29 “Product Warranties” means those warranties relating to the Product or Process specifically set forth in
Section 5.2.2. 
 1.30 “Production Rerun” has the meaning set forth in Section 5.4.1. 

1.31 “Production Term” has the meaning set forth in Section 4.2. 

1.32 “Quality Agreement” means the Quality Agreement entered into by the Parties simultaneously with the execution hereof
relating to a Product. 
 1.33 “Regulatory Approval” means the approval by the FDA to market and sell the Product in the
United States. 
 1.34 “Remaining CLIENT Property” has the meaning set forth in Section 7.2. 

1.35 “SOP” means a standard operating procedure. 

1.36 “Specifications” means the Product specifications set forth in the Statement of Work or as modified by the Parties in
connection with the production of a particular Batch of Product hereunder. 
  
 [*] =
Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -3- 

 1.37 “Statement of Work” means a plan to develop a Process or Product that is
executed by the Parties and attached hereto as Appendix A or later becomes attached through an amendment by the Parties. The first Statement of Work, which is attached hereto, shall be numbered Appendix A-1 and, when executed and
delivered by the Parties, is hereby incorporated and made a part of this Agreement. It is contemplated that each separate project shall have its own Statement of Work. As each subsequent Statement of Work is agreed to by the Parties, each shall
state that it is to be incorporated and made a part of this Agreement and shall be consecutively numbered as A-2, A-3, etc. 
 1.38
“Third Party” means any party other than LWI, CLIENT or their respective Affiliates. 
  

	2.	STATEMENTS OF WORK - PROCESS AND PRODUCT DEVELOPMENT; CLIENT TECHNOLOGY TRANSFER;
PROCESS OR PRODUCT MANUFACTURE 

 2.1 Statement of Work.
Prior to performing any Process or Product development, CLIENT Technology Transfer, or Product manufacture, the Parties will collaborate to develop a Statement of Work, describing the activities to be performed by the Parties, or to be subcontracted
by LWI to Third Parties. Once agreed to by the Parties, the Statement of Work shall be executed by each of the Parties and appended hereto as part of Appendix A and shall be a part hereof. In the event of a conflict between the terms and
conditions of this Agreement and any Statement of Work, the terms and conditions of this Agreement shall control. 
 2.2 Modification of
Statement of Work. Should CLIENT want to change a Statement of Work or to include additional services to be provided by LWI, CLIENT may propose to LWI an amendment to the Statement of Work with the desired changes or additional services
(“Change Order”). After LWI utilizes its best efforts to accommodate CLIENT’s reasonable requests, if LWI determines that it has the resources and capabilities to accommodate such Change Order, LWI will prepare a modified
version of the Statement of Work reflecting such Change Order (including, without limitation, any changes to the estimated timing, estimated charges or scope of a project) and will submit such modified version of the Statement of Work to CLIENT for
review and comment. The modified Statement of Work shall be binding on the Parties only if it refers to this Agreement, states that it is to be made a part thereof, and is signed by both Parties, whereafter such modified version of the Statement of
Work will be deemed to have replaced the prior version of the Statement of Work. Notwithstanding the foregoing, if a modified version of the Statement of Work is not agreed to by both Parties, the existing Statement of Work shall remain in effect
unless terminated by CLIENT upon [ * ] days prior written notice to LWI, in which case CLIENT shall be responsible for the fees set forth in Section 14.6.3. 

2.3 CLIENT Deliverables. 

2.3.1 Within the time period specified in a Statement of Work, CLIENT will provide LWI with (a) the materials listed in the Statement of
Work for which CLIENT is responsible for delivering to LWI, and any handling instructions, protocols, SOPs and other documentation necessary to maintain the properties of such materials for the performance of the Statement of Work, and (b) any
related protocols, SOPs and other information and documentation 
  
 [*] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -4- 

 
in possession or control of CLIENT and necessary for the performance of the Statement of Work, and for the preparation of the Master Production Record in conformance with cGMP, including, without
limitation, process information, SOPs, development data and reports, quality control assays, raw material specifications (including vendor, grade and sampling/testing requirements), product and sample packing and shipping instructions, and product
specific cleaning and decontamination information (collectively, the “CLIENT Development Materials”). For clarity, CLIENT Development Materials includes CLIENT’s PANC 10.3 and PANC 6.05 cell lines (the “Cell
Lines”). 
 2.3.2 LWI agrees that the CLIENT Development Materials shall only be used as specified in writing by CLIENT in
this Agreement or the applicable Statement of Work, and not for any other purpose. CLIENT Development Materials shall be maintained, handled and stored in accordance with the written directions of CLIENT. Title to the CLIENT Development Materials
shall at all times remain in CLIENT. LWI agrees that it shall not make any claim or place any lien or encumbrance on any CLIENT Development Materials. Upon direction of CLIENT, LWI shall provide CLIENT with an accounting of the CLIENT Development
Materials and a list of persons with access to the CLIENT Development Materials, and will return to CLIENT all CLIENT Development Materials supplied by CLIENT, except to the extent such CLIENT Development Materials are no longer available to return
as the materials have been utilized, or are incorporated in Product or work in process in connection with the services performed hereunder. Risk of loss to Cell Lines shall remain with LWI while CLIENT Developed Materials are in LWI’s control,
except for any risk of loss that is inherent to the Cell Lines and so long as the loss is unrelated to the negligent or willful acts or omissions of LWI or its agents. CLIENT shall have the absolute right upon reasonable notice and reasonable
request to recover the CLIENT Development Materials, except to the extent such CLIENT Development Materials are no longer available to return as the materials have been utilized or are incorporated in Product or work in process in connection with
the services performed hereunder, and LWI shall cooperate in the same. Title to each cell line made from Cell Lines shall vest in CLIENT after CLIENT pays LWI for the cost for the creation of each such cell line, as such cost is specifically set
forth in the relevant Statement of Work. 
 2.3.3 LWI covenants not to share any CLIENT Development Materials with any person located
outside the United States without the express prior written consent of CLIENT, which consent shall not be unreasonably withheld or delayed if (i) LWI demonstrates to CLIENT that such sharing is essential to the purposes of this Agreement and no
reasonable alternative is available and (ii) the receiving party, LWI, and CLIENT have executed appropriate written agreements that secure and protect the CLIENT Development Materials and in which LWI takes responsibility for the same. 

2.4 Performance by LWI. Subject to the provision by CLIENT of the CLIENT Development Materials pursuant to Section 2.3, LWI will
use commercially reasonable efforts to perform, directly or, if specifically contemplated in the Statement of Work or approved in writing in advance by CLIENT (such approval not to be unreasonably withheld or delayed), through a Third Party
contractor, the work described in a Statement of Work in a professional and workmanlike manner in accordance with the terms of this Agreement on the timeline set forth in the Statement of Work. LWI will promptly notify CLIENT of any material delays
that arise during the performance of the Statement of Work and the Parties will promptly meet to determine whether 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -5- 

 
there is any reasonable remediation that might lessen the impact of any such delay. LWI shall be responsible for any delays that are within its reasonable control or that of any of its Affiliates
or permitted subcontractors. All work will be completed by LWI at the LWI facility located in Walkersville, Maryland, USA, unless otherwise approved in writing by CLIENT. 

2.5 Subcontracting. LWI may not subcontract with any Third Party to perform any of its Product-specific obligations under this
Agreement without the prior written consent of CLIENT, which consent shall not be unreasonably withheld or delayed. LWI shall be entitled to instruct one or more of its Affiliates to perform any of LWI’s obligations in this Agreement, but LWI
shall remain fully responsible in respect of those obligations. LWI will be solely responsible for the performance of any Affiliate or permitted subcontractor, and for costs, expenses, damages, or losses of any nature arising out of such performance
as if such performance had been provided by LWI itself under this Agreement and to which the terms of this Agreement shall apply. LWI will cause any such Affiliate or permitted subcontractor to be bound by, and to comply with, the terms of this
Agreement or any other ancillary agreements the Parties may enter into in connection with the provision of the services, as applicable, including, without limitation, all confidentiality, quality assurance, regulatory and other obligations and
requirements of LWI. 
 2.6 Management. Each Party shall appoint one person to serve as a point person for matters related to this
Agreement. CLIENT will initially be represented by [ * ]. LWI will initially be represented by [ * ]. 
  

	3.	CLIENT TECHNOLOGY TRANSFER 

 3.1 By CLIENT to
LWI. Based on the information provided by CLIENT and including process changes developed by LWI pursuant to any applicable Statement of Work, LWI will prepare the Master Production Record for the Process in accordance with the schedule
set forth in the Statement of Work. CLIENT will inform LWI of any specific requirements CLIENT may have relating to the Master Production Record, including, without limitation, any information or procedures CLIENT wishes to have incorporated
therein. Except for LWI Operating Documents, if LWI would like CLIENT to consider including as part of the Master Production Record the use of any assay, medium, or other intellectual property or technology that is proprietary to LWI or any Third
Party, LWI will inform CLIENT of such desire and the Parties will meet to discuss and attempt to agree in good faith on the terms of use of such materials or technology in the Process. (For clarity, the terms for use of LWI Intellectual Property are
set forth in Section 11.2.) In addition, LWI will disclose to CLIENT all reasonable alternatives of which it is aware so that all reasonable alternatives are considered and discussed by the Parties. 

3.2 CLIENT will cooperate with LWI to assist LWI to develop the Master Production Record and Process, including, without limitation, by
providing LWI with additional information and procedures in CLIENT’s control that is required to create the Master Production Record, Process, which may include the following: (i) manufacturing process information, SOPs, development
reports, (ii) quality control assays, (iii) raw material specifications (including vendor, grade and sampling/testing requirements), (iv) Product and sample packing and shipping instructions, and (v) Product specific cleaning and
decontamination information. 
  
 [*] = Certain confidential information contained in
this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -6- 

 3.3 LWI will deliver a draft version of the Master Production Record to CLIENT for its review and
approval in accordance with the schedule set forth in the Statement of Work. CLIENT will notify LWI in writing of any objections it has to the draft Master Production Record, and upon such notification, representatives of LWI and CLIENT will meet
promptly to resolve such objections. Upon CLIENT’s written acceptance of the draft Master Production Record, or in the event that CLIENT does not submit a written notice setting forth CLIENT’s objections to the draft Master Production
Record within [ * ] business days following receipt of such draft by CLIENT, such draft will be deemed approved by CLIENT, provided that CLIENT may request and shall be permitted additional time if reasonably requested by CLIENT, in which case
CLIENT shall be responsible for any costs incurred by LWI arising from such additional time. 
  

	4.	MANUFACTURE OF PRODUCT; ORDER PROCESS; DELIVERIES 

4.1 Draft Plan. To the extent not already delivered prior to the execution of any Statement of Work, LWI will deliver to CLIENT for
review and comment, a proposed draft plan describing the activities to be performed by LWI, or to be subcontracted by LWI to Third Parties, in the production of a Product (the “Draft Plan”). Once LWI delivers to CLIENT the proposed
Draft Plan, the parties will meet to decide whether to issue a new Statement of Work pursuant to Section 2.1, or to modify an existing Statement of Work pursuant to Section 2.2, based on that Draft Plan and any agreed upon modifications.

 4.2 Manufacture by LWI. During the time period specified in any Statement of Work during which Process and Product will be
developed and manufactured which will end only after completion of the services and delivery of the deliverables set forth in the Statement of Work (the “Production Term”), LWI will use its commercially reasonable best efforts to
develop, manufacture, package, ship, handle quality assurance and quality control for the Product and perform all other services and deliver all deliverables as set forth in the Statement of Work, and to deliver to CLIENT the quantities of Product
requested by CLIENT in the Statement of Work, all in accordance with the terms of this Agreement. 
 4.3 Packaging and
Shipping. LWI will package and label the Product for shipment in accordance with the Master Production Record and LWI’s standard practices in effect at the time of performance by LWI. LWI will ship the Product [ * ] (Incoterms 2010)
[ * ] to a common carrier designated by CLIENT to LWI in writing not less than [ * ] days prior to the delivery date that is either set forth in the Statement of Work or otherwise agreed in writing by the Parties. CLIENT will provide
to LWI its account number with the selected carrier and will pay for all shipping costs in connection with each shipment of Product. LWI will use commercially reasonable efforts to deliver each shipment of Product to CLIENT on the requested delivery
date for such shipment. LWI will promptly notify CLIENT if LWI reasonably believes that it will be unable to meet a delivery date and the reasons therefor. CLIENT shall be required to take delivery of a Batch of Product within [ * ] days
after acceptance of such Batch in accordance with Section 5.2 (the “Delivery Period”). Notwithstanding anything to the contrary, title in all Product shall pass to CLIENT upon delivery to the carrier. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -7- 

 4.4 Quality Agreement. Promptly after the Effective Date, the Parties shall enter into a
separate Quality Agreement setting forth the terms for Product quality. Such Quality Agreement shall be separately appended to this Agreement. 

4.5 Records. LWI will maintain accurate records for the production of the Product, as required by all Applicable Laws. LWI will retain
possession of the Master Production Record, all Batch Records and LWI Operating Documents, and will make copies thereof available to CLIENT upon CLIENT’s request and at CLIENT’s expense. CLIENT will have the right to use and reference any
of the foregoing in connection with a filing for Regulatory Approval of the Product, as per Section 8.4, or as otherwise authorized by the Agreement. LWI Operating Documents will remain LWI Confidential Information. 

4.6 CLIENT Access. 
 4.6.1
CLIENT’s employees and agents (including its independent contractors) (collectively, “CLIENT Personnel”) may participate in the development of the Product, Process, and Master Production Record and the production of the Product
to the extent agreed in advance by the Parties or as may be contemplated in this Agreement. CLIENT Personnel working at the Facility are required to comply with LWI Operating Documents and any other applicable LWI facility and/or safety policies.
For the avoidance of doubt, CLIENT Personnel may not physically participate in the production or manufacture of any Product that may be used in or on humans, provided that CLIENT Personnel shall be permitted to observe preparation for and Product
production. 
 4.6.2 CLIENT Personnel working at the Facility will be and remain employees of CLIENT, and CLIENT will be solely responsible
for the payment of compensation for such CLIENT Personnel (including applicable Federal, state and local withholding, FICA and other payroll taxes, workers’ compensation insurance, health insurance, and other similar statutory and fringe
benefits). CLIENT covenants and agrees to maintain workers’ compensation benefits and employers’ liability insurance as required by applicable Federal and Maryland laws with respect to all CLIENT Personnel working at the Facility. 

4.6.3 CLIENT will pay for the actual cost of repairing or replacing to its previous status any property of LWI damaged or destroyed by CLIENT
Personnel, provided CLIENT shall not be liable for repair or replacement costs resulting from ordinary wear and tear. 
 4.6.4 CLIENT
Personnel visiting or having access to the Facility will abide by LWI standard policies, operating procedures and the security procedures established by LWI. CLIENT will be liable for any breaches of security by CLIENT Personnel. All CLIENT
Personnel will agree to abide by LWI policies and SOPs established by LWI, and will sign an appropriate confidentiality agreement. 
 4.6.5
CLIENT will indemnify and hold harmless LWI from and against any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys’ fees and expenses) arising out of any injuries suffered by CLIENT Personnel while at the
Facility or elsewhere, except to the extent caused by the negligence or willful misconduct on the part of any LWI Party or breach of this Agreement by LWI. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -8- 

 4.7 Disclaimer. LWI covenants that it will not engage in any Product refinement or development of
the Product, other than as expressly set forth in this Agreement and the Statement of Work. The Parties certify that (i) as of the Effective Date no LWI Parties have participated in the invention or testing of any Product, and (ii) LWI
Parties have not evaluated whether Product is safe and effective for use in humans or otherwise. 
  

	5.	PRODUCT WARRANTIES; ACCEPTANCE AND REJECTION OF PRODUCTS 

5.1 Product Warranties. LWI warrants that any Product manufactured by LWI pursuant to this Agreement, at the time of delivery pursuant
to Section 4.3: (a) conforms to the Specifications; (b) was manufactured in accordance with the Master Production Record; (c) was manufactured in accordance with cGMP using a process, components and a facility that comply with
all Applicable Laws; and (d) is delivered free and clear of any liens or encumbrances of any kind. For the purposes of this Agreement, compliance with the product warranties set forth in Sections 5.1(a) – (c) shall mean the Product is
not “adulterated”. The foregoing are collectively referred to as the “Product Warranties”. 
 5.2 Approval of
Shipment. 
 5.2.1 When the Product ordered by CLIENT is ready for delivery, LWI will notify CLIENT and supply CLIENT with the
Batch Documentation. If a Batch of Product conforms to the Product Warranties, then a certificate of compliance will be completed and approved by LWI. This certificate of compliance, a certificate of analysis, the Specifications, a complete and
accurate copy of the consolidated Batch Records, and the Process description (collectively, the “Batch Documentation”) for such Batch of Product will be provided to CLIENT within [ * ] calendar days of completing testing,
either electronically through a secure portal or by a reputable overnight courier or by registered or certified mail, postage prepaid, return receipt required to verify delivery date. Upon request, LWI will also provide CLIENT with all results
relating to the manufacture of each Batch of Product, which results are set forth in the Batch Record. 
 5.2.2 Within [ * ] calendar
days after CLIENT’s receipt of such Batch Documentation regarding such Product (the “Acceptance Period”), CLIENT shall determine by review of such Batch Documentation whether or not the Batch Documentation reflects that the
given Batch conforms to the Product Warranties set forth in Section 5.1 above, except to the extent a warranty cannot be confirmed by reviewing such documentation. Notwithstanding the foregoing, if CLIENT reasonably requests to extend the
Acceptance Period and its review of the Batch Documentation has commenced and CLIENT is diligently reviewing the Batch Documentation within such [ * ]-day period, the Acceptance Period shall be extended to a period not to exceed [ * ]
days, so long as the CLIENT is making diligent efforts, and assuming LWI cooperates fully therewith. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -9- 

 5.2.3 Non-Conforming Batch(es). If CLIENT asserts that the Product does not comply as
described in the prior sentence with the Product Warranties set forth in Section 5.1 above, CLIENT will deliver to LWI, in accordance with the notice provisions set forth in Section 17.3 hereof, written notice of disapproval (the
“Disapproval Notice”) of such Product, stating in reasonable detail the basis for such assertion of non-compliance with the Product Warranties. If a valid Disapproval Notice is received by LWI during the Acceptance Period, then LWI
and CLIENT will provide one another with all related paperwork and records (including, but not limited to, quality control tests) relating to both the production of the Product and the Disapproval Notice. If a valid Disapproval Notice is not
received during the Acceptance Period, the Product will be deemed accepted and ready for shipment and the Product shall be delivered to CLIENT. CLIENT shall accept delivery thereof within [ * ] days after such acceptance. Risk of loss to such
Product shall pass to CLIENT at the time of delivery to the common carrier pursuant to Section 4.3. 
 5.3 Dispute Resolution.
LWI and CLIENT will attempt to resolve any dispute regarding the conformity of a shipment of Product with the Product Warranties. If such dispute cannot be settled within [ * ] days of the submission by each Party of such related paperwork
and records to the other Party, and if the Product is alleged not to conform with the Product Warranties set forth in Section 5.1, then CLIENT will submit a sample of the Batch of the disputed shipment to an independent testing laboratory of
recognized repute selected by CLIENT and approved by LWI (such approval not to be unreasonably withheld) for analysis, under quality assurance approved procedures, of the conformity of such shipment of Product with the Specifications. If the
existence or cause of the alleged nonconformity cannot be determined solely by laboratory testing, then the CLIENT shall also select appropriate experts of recognized repute and approved by LWI (such approval not to be unreasonably withheld) in
order to conduct an audit of documents and facilities in order to confirm conformity to of Product with Product Warranties. The costs associated with such analyses by such independent testing laboratory and experts will be paid by the Party whose
assessment of the conformity of the shipment of Product with the Product Warranties was mistaken. 
 5.4 Remedies for Non-Conforming
Product. 
 5.4.1 Until the Process is submitted as part of a biologic license application and is approved by the FDA, in the
event that the Parties agree, or an independent testing laboratory or experts determine, pursuant to Section 5.3, a Batch of Product materially fails to conform to the Product Warranties due to the failure of: (a) LWI to properly execute
the Master Production Record in respect of the manufacture of the Product, (b) LWI to comply with cGMP, (c) LWI’s negligence or willful misconduct, or (d) LWI facilities or utilities then, at CLIENT’s request, LWI will
promptly produce for CLIENT sufficient quantities of Product to replace the non-conforming portion of such Batch of Product (the “Production Rerun”), in accordance with the provisions of this Agreement and at no additional cost to
CLIENT. If the CLIENT has not yet paid for the failed Batch of Product, then CLIENT will be billed when it receives the replacement. 

5.4.2 Until the Process is submitted as part of a biologic license application and is approved by the FDA, in the event that the Parties
agree, or an independent testing laboratory or experts determine, pursuant to Section 5.3, that a Batch of Product materially fails to conform to 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -10- 

 
the Product Warranties for any reason other than as set forth in Section 5.4.1, then LWI shall have no liability to CLIENT with respect to such Batch and LWI will, at CLIENT’s request,
produce for CLIENT as soon as practicable a Production Rerun at CLIENT’s expense. 
 5.4.3 After the Process is submitted as part of a
biologic license application and once it is approved by the FDA, in the event that the Parties agree, or an independent testing laboratory or experts determine, pursuant to Section 5.3, that a Batch of Product materially fails to conform to the
Product Warranties and such failure is (a) not the result of an inherent characteristic of the Process, Materials, or CLIENT Development Materials, including any cell lines originally provided by CLIENT, or (b) not the result of
circumstances outside of LWI’s reasonable control or the control of its Affiliates or permitted contractors, LWI will produce for CLIENT as soon as practicable a Production Rerun, in accordance with the provisions of this Agreement and at no
additional cost to CLIENT. 
 5.4.4 After the Process is submitted as part of a biologic license application and once it is approved by the
FDA, in the event that the Parties agree, or an independent testing laboratory or experts determine, pursuant to Section 5.3, that a Batch of Product materially fails to conform to the Product Warranties as a result of (i) an inherent
characteristic of the Process, Materials, or CLIENT Development Materials, including any of the cell lines originally provided by CLIENT, or (ii) a failure that is the result of circumstances outside of LWI’s reasonable control or the
control of its Affiliates or permitted contractors, then LWI shall have no liability to CLIENT with respect to such Batch and LWI will, at CLIENT’s request, produce for CLIENT as soon as practicable a Production Rerun at CLIENT’s expense.

 5.4.5 Except with respect to [ * ], CLIENT [ * ], and in furtherance thereof, [ * ]. 

5.4.6 Each Party will promptly notify the other in the event that it becomes aware of any circumstance that might be reasonably expected to
result in a Product recall or market withdrawal. In the event that the CLIENT determines that a recall or market withdrawal of Product is needed, CLIENT shall manage and lead such recall or withdrawal and LWI shall fully cooperate with CLIENT in
connection therewith. The administrative costs of a recall or withdrawal will be borne by CLIENT except to the extent that the recall or withdrawal is the result of a negligent or willful act or omission of LWI. 

5.5 Remedies for Non-Conforming Services. 

5.5.1 Notwithstanding anything to the contrary herein, if LWI provides any services, other than manufacturing of the Product to which
Section 5.4 shall apply, which services fail to conform to agreed upon written instructions or which are not performed according to customary professional standards of established practice in the industry or the applicable requirements of this
Agreement, CLIENT may require LWI to (i) reperform such services at no additional cost to CLIENT or (ii) if LWI does not or cannot promptly reperform such service, or if CLIENT has a reasonable basis to move the services to another
manufacturer taking into account all relevant factors, promptly repay to CLIENT any monies paid by CLIENT to LWI for the performance of such services. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -11- 

 5.5.2 Except with respect to [ * ], CLIENT [ * ], and in furtherance thereof, [
* ]. 
  

	6.	DAMAGE OR DESTRUCTION OF MATERIALS AND/OR PRODUCT 

6.1 Remedies. If during the manufacture of Product pursuant to this Agreement, Product and/or Materials are destroyed or damaged by LWI
Personnel, and such damage or destruction resulted from LWI’s failure to execute the Process in conformity with the Master Production Record or is otherwise attributable to the negligence or willful misconduct of LWI Personnel or the breach of
this Agreement by LWI, then, except as provided in Section 6.2 below, LWI, as soon as it is commercially practicable to do so, will provide CLIENT with additional Product production time equal to the actual time lost because of the destruction
or damage of the Product and/or Materials and will [ * ]. CLIENT acknowledges and agrees that [ * ], and in furtherance thereof, [ * ]. 

6.2 Limitations. Notwithstanding anything to the contrary set forth in the preceding Section 6.1, if during the manufacture of
Product pursuant to this Agreement, Product or Materials are destroyed or damaged by LWI Personnel while LWI Personnel were acting at the written direction of CLIENT Personnel, unless CLIENT is directing during active production, in which case such
direction may not be in writing, then LWI will have no liability to CLIENT as the result of destruction or damage arising from the competent execution of such directions. 
  

	7.	STORAGE OF MATERIALS 

 7.1
Pre-Production. LWI will store at the expense of CLIENT any CLIENT Development Materials, equipment or other property delivered pursuant to the Statement of Work or the Draft Plan to the Facility by CLIENT more than [ * ] days prior to
the commencement date. The storage rates will be set forth in the Statement of Work and may be amended from time to time by LWI. No storage fees will be charged during the period starting [ * ] days prior to the commencement date and ending
upon the expiration or termination of the Production Term and for [ * ] days thereafter. 
 7.2 Post-Production. LWI will
store at the Facility free of charge any in–process materials, Materials paid for by CLIENT, equipment and other CLIENT property (other than Product manufactured hereunder) that remains at the Facility on the date of expiration or termination
of the Production Term (collectively “Remaining CLIENT Property”), for up to [ * ] calendar days. In the event that LWI continues to store such Remaining CLIENT Property, CLIENT will pay to LWI a storage charge at LWI’s
then-standard storage rates for the period beginning on the [ * ] day after the expiration or termination of the Production Term through the date that the storage terminates. LWI shall have no right to destroy Remaining CLIENT Property. 

7.3 Product. Notwithstanding the foregoing, if CLIENT fails to take delivery of a Product within [ * ] days after the expiration
or termination of the Production Term, CLIENT will pay to LWI a storage charge at [ * ] times LWI’s then-standard storage rate, which shall begin accruing on the first day following the expiration of the applicable Delivery Period. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -12- 

	8.	REGULATORY MATTERS 

 8.1 Permits and Approvals.
During the Production Term, LWI will use commercially reasonable efforts to maintain any licenses, permits and approvals necessary for the manufacture of the Product in the Facility. LWI will promptly notify CLIENT if LWI receives notice that any
such license, permit, or approval is or may be revoked or suspended. 
 8.2 Inspections/Quality Audit by CLIENT. Up to one time per
calendar year during the Production Term without cause and otherwise with cause, and upon not less than [ * ] days’ prior written notice, LWI will permit CLIENT to inspect and audit the parts of the Facility where the manufacture of the
Product is carried out in order to assess LWI’s compliance with this Agreement, and to discuss any related issues with LWI’s management personnel. CLIENT Personnel engaged in such inspection will abide by the terms and conditions set forth
in Sections 4.6.1, 4.6.4, and 10. If any deficiencies are noted, LWI shall not more than [ * ] days thereafter provide to CLIENT a remediation plan, which plan will be commented upon by CLIENT. LWI will use commercially reasonable efforts to
take all reasonable comments to the plan and then execute the plan as soon as reasonably practicable thereafter so as to attempt to limit the duration of any delay. 

8.3 Inspections by Regulatory Agencies. LWI will allow representatives of any regulatory agency to inspect the relevant parts of any
LWI Facility relevant to Product or this Agreement, and to inspect the Master Production Record and Batch Records to verify compliance with cGMP and other practices or regulations and will promptly notify CLIENT of the scheduling or initiation of
any such inspection relating to the manufacture of Product. LWI will notify CLIENT of any planned governmental or regulatory authority inspections that are reasonably likely to involve or impact Product not less than [ * ] calendar days prior
to the inspection. CLIENT shall have the right to observe such inspection if any material portion of the inspection relates specifically to Product. LWI will promptly, but in no more than [ * ] business days (i) send to CLIENT a copy of
any reports, citations, or warning letters received by LWI and (ii) convey to CLIENT any oral comments of regulatory authorities, in connection with an inspection of a regulatory agency to the extent such documents or comments relate to or
affect the manufacture of the Product, and LWI will answer any and all questions that CLIENT may have related thereto. LWI will share with CLIENT its plan to promptly remedy any deficiencies noted by a regulatory agency and LWI will implement such
plan as soon as reasonably practicable thereafter. If such remedy is specifically related to Product, LWI will allow CLIENT the opportunity to comment before submitting a response to the governmental or regulatory authority. 

8.4 Regulatory Submissions. CLIENT will be responsible for obtaining, at its expense, all regulatory and governmental approvals and
permits necessary for CLIENT’s use of any Product developed and/or manufactured under this Agreement, including, without limitation, IND amendments and any analogous submissions filed with the appropriate governmental or regulatory authority.
LWI will be responsible, at CLIENT’s expense, for providing CLIENT with relevant supporting data and information relating to the development and/or manufacture of Product (or any component thereof) necessary for obtaining such approvals;
however, any trade secrets or confidential or proprietary information of LWI may be provided by LWI directly to the appropriate governmental or regulatory authority in its drug master file (“DMF”), and LWI shall permit CLIENT and/or its
licensees to refer to such DMF as part of CLIENT’s submissions to such governmental or regulatory authority. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -13- 

	9.	FINANCIAL TERMS 

 9.1 Payments. CLIENT will make
payments to LWI for professional fees, pass through costs and other fees or costs in the amounts and at the times set forth in the Statement of Work, upon receipt of an invoice from LWI as set forth in Section 9.5. Any agreed advances and terms
related thereto shall also be included in any Statement of Work. In the event that CLIENT has not paid an undisputed invoice within [ * ] business days of the applicable due date (as established by this Agreement) and such invoice is not
disputed by CLIENT in good faith, LWI may consider such nonpayment a material breach under Section 14.2, subject to the notice and cure provisions set forth therein. Further, in addition to all other remedies available to LWI and remedies and
defenses available to CLIENT, in the event that CLIENT has not paid an invoice within [ * ] business days of the applicable due date (as established by this Agreement) and such invoice is not disputed by CLIENT in good faith, LWI may [ *
], provided that CLIENT shall remain liable for all fees owed pursuant to the Statement of Work [ * ]. 
 9.2 Pass-through
Costs. Pass through costs shall be invoiced to CLIENT at actual cost plus any additional fees set forth in the applicable Statement of Work. Payment terms for pass through costs are set forth in each relevant Statement of Work. 

9.3 Advance Payments. The amount of any advance payment shall be defined in the Statement of Work (the “Advance Payment”) and
shall not exceed [ * ] of the total estimated payment due under such Statement of Work. For Statements of Work whose term are initially estimated to be less than or equal to [ * ] months, advances shall be applied equally to the
final [ * ] invoices. For Statements of Work whose term are initially estimated to be more than [ * ] months, advances shall be applied equally to the final [ * ] invoices.

9.4 Progress and Estimates. The Parties shall meet at least one time per month to discuss any active Statements of Work and the
progress of each project against the anticipated timelines and costs estimated therefor. At such meetings and otherwise upon the request of CLIENT, LWI will provide to CLIENT with updated estimates of project costs and up to date progress against
initial budget. Increases of more than [ * ] percent of any material line item of the budget set forth in a Statement of work must be approved by CLIENT in advance in writing. LWI shall not exceed any estimated budget set forth in a Statement
of Work without the prior written consent of CLIENT. 
 9.5 Invoices. Within [ * ] days of the end of each month during which
charges were incurred, LWI will provide CLIENT with an invoice setting forth a detailed account of any fees, expenses, or other payments payable by CLIENT under this Agreement for the preceding month. The amounts set forth in each such invoice will
be due and payable within [ * ] days of receipt of such invoice by CLIENT. 
 9.6 Taxes. CLIENT agrees that it is responsible
for and will pay any sales, use or other taxes (the “Taxes”) resulting from LWI’s production of Product under this Agreement (except for 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -14- 

 
income or personal property taxes payable by LWI). To the extent not paid by CLIENT, CLIENT will indemnify and hold harmless the LWI Parties from and against any and all penalties, fees, expenses
and costs whatsoever in connection with the failure by CLIENT to pay the Taxes. LWI will not collect any sales and use taxes from CLIENT in connection with the production of any Product hereunder if CLIENT provides to LWI the appropriate valid
exemption certificates. 
 9.7 Interest. Any fee, charge or other payment due to LWI by CLIENT under this Agreement that is not paid
within [ * ] days after it is due will accrue interest on a daily basis at a rate of [ * ]% per month (or the maximum legal interest rate allowed by Applicable Laws, if less) from and after such date. 

9.8 Method of Payment. All payments to LWI hereunder by CLIENT will be in United States currency and will be by check, wire transfer,
money order, or other method of payment approved by LWI. Bank information for wire transfers is as follows: 
 Mailing address for wire
transfer payments: 
 [ * ] 
 ABA# for wires and ACH for our
account = [ * ] 
 Lockbox # [ * ] 
 Account #
[ * ] 
 Lonza Walkersville, Inc. 
 12261 Collections
Center Drive 
 Chicago, Illinois, 60693 
 9.9
Cost Adjustments. Beginning [ * ] months after the effective date of a Statement of Work, LWI may [ * ] adjust the various costs and rates, including the professional fees, set forth in the Statement of Work attached hereto [
* ]; provided, however, that any [ * ] shall not exceed [ * ]. LWI agrees to provide CLIENT with written notice not less than [ * ] days prior to such cost adjustment. In the event of a material increase in the costs of LWI,
which increase is out of the reasonable control of LWI, for (i) LWI’s compliance with a new or changed environmental or regulatory standard or (ii) a component of LWI’s suite fees, upon prior written notice to CLIENT of not less
than [ * ] days and having provided to CLIENT at the time of such notice, reasonable detail and calculations in justification of such increased costs, as well as answers to all related questions of CLIENT, LWI may increase its fees for such
costs, provided that (i) if CLIENT reasonably requests additional information and such [ * ] day notice period expires, LWI shall not increase the price until [ * ] days after such additional information is provided to CLIENT,
provided that any such price increase shall be retroactive to the date on which the [ * ] day notice period expires or the date on which LWI’s costs are actually increased, whichever is later, (ii) if the change is specific to the
Product or Process, CLIENT shall bear all of such increase and (iii) [ * ]. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -15- 

	10.	CONFIDENTIAL INFORMATION 

 10.1 Definition.
“Confidential Information” means all technical, scientific and other know-how and information, trade secrets, knowledge, technology, means, methods, processes, practices, formulas, instructions, skills, techniques, procedures,
specifications, data, results and other material, pre-clinical and clinical trial results, manufacturing procedures, test procedures and purification and isolation techniques, and any tangible embodiments of any of the foregoing, and any scientific,
manufacturing, marketing and business plans, any financial and personnel matters relating to a Party or its present or future products, sales, suppliers, customers, employees, investors or business, that has been disclosed by or on behalf of such
Party or such Party’s Affiliates to the other Party or the other Party’s Affiliates either in connection with the discussions and negotiations pertaining to this Agreement or in the course of performing this Agreement. Without limiting the
foregoing, the terms of this Agreement will be deemed “Confidential Information” and will be subject to the terms and conditions set forth in this Article 10. 

10.2 Exclusions. Notwithstanding the foregoing Section 10.1, any information disclosed by a Party to the other Party will not be
deemed “Confidential Information” to the extent that such information: 
 (a) at the time of disclosure is in the public domain;

 (b) becomes part of the public domain, by publication or otherwise, through no fault of the Party receiving such information; 

(c) at the time of disclosure is already in possession of the Party who received such information, as established by contemporaneous written
records; 
 (d) is lawfully provided to a Party, without restriction as to confidentiality or use, by a Third Party lawfully entitled to
possession of such Confidential Information; or 
 (e) is independently developed by a Party without use of or reference to the other
Party’s Confidential Information, as established by contemporaneous written records. 
 10.3 Disclosure and Use Restriction.
Except as expressly provided herein, the Parties agree that for the term of the Agreement and the five-year period following any termination of the Agreement, each Party and its Affiliates will keep completely confidential and will not publish or
otherwise disclose any Confidential Information of the other Party, its Affiliates or sublicensees, except in accordance with Section 10.4. Neither Party will use Confidential Information of the other Party except as necessary to perform its
obligations or to exercise its rights under this Agreement. LWI will not share any of CLIENT’s Confidential Information with any party outside the United States without CLIENT’s express prior written consent. 

10.4 Permitted Disclosures. Each receiving Party agrees to (i) institute and maintain security procedures to identify and account
for all copies of Confidential Information of the disclosing Party and (ii) limit disclosure of the disclosing Party’s Confidential Information to its Affiliates and each of its and their respective officers, directors, employees, agents,
consultants and independent contractors having a need to know such Confidential Information for purposes of 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -16- 

 
this Agreement; provided that such Affiliates and each of its and their respective officers, directors, employees, agents, consultants and independent contractors are informed of the terms of
this Agreement and are subject to obligations of confidentiality, non-disclosure and non-use similar to those set forth herein. 
 10.5
Government-Required Disclosure. If a duly constituted government authority, court or regulatory agency orders that a Party hereto disclose information subject to an obligation of confidentiality under this Agreement, such Party shall comply
with the order, but shall notify the other Party as soon as possible, so as to provide the said Party an opportunity to apply to a court of record for relief from the order. 

10.6 Publicity. Neither Party will refer to, display or use the other’s name, trademarks or trade names confusingly similar
thereto, alone or in conjunction with any other words or names, in any manner or connection whatsoever, including any publication, article, or any form of advertising or publicity, except with the prior written consent of the other Party.

  

	11.	INTELLECTUAL PROPERTY 

 11.1 Ownership. 

11.1.1 Each Party shall own all its respective proprietary Intellectual Property made, conceived or reduced to practice by or for such Party
other than in connection with this Agreement and no right shall be granted to other Party in such Intellectual Property unless specifically set forth otherwise herein. Except as expressly otherwise provided herein, ownership of any Intellectual
Property that is developed, conceived, invented, first reduced to practice or made in connection with the performance under this Agreement shall be determined in accordance with United States law and ownership shall follow inventorship. 

11.1.2 The Process, Specifications, CLIENT New IP and any improvements or modifications thereto developed during the term of this Agreement
are hereby the sole and exclusive property of CLIENT (the “CLIENT Process”), provided that LWI is the owner of LWI Intellectual Property, LWI New IP, Master Production Record and the LWI Operating Documents and such LWI Operating
Documents may not be shared with a Third Party. For clarity, LWI Intellectual Property and LWI New IP that is part of the Master Production Record or Process, and the Master Production Record, except the LWI Operating Documents, is subject to the
license set forth in this Agreement. LWI hereby assigns to CLIENT all its right title and interest in and to the Process, Specifications, and any improvements or modifications thereto developed during the term of this Agreement subject to its rights
described herein. LWI hereby grants to CLIENT an irrevocable unrestricted royalty-free right to use for [ * ] the Master Production Record (but not including LWI Operating Documents referred to in such Master Production Record and LWI
Intellectual Property (including without limitation LWI New IP) included in such Master Production Record, which LWI Intellectual Property will be identified to CLIENT upon CLIENT’s request and which is subject to Section 11.2.2), which
right is not executory (there being no obligations on the part of CLIENT to be performed) and shall never be subject to contingency, rejection, termination, modification or set off. LWI also hereby grants to CLIENT prompt and full access to, at
reasonable times and on reasonable notice to LWI, the original copy of the Master Production Record, and agrees to provide copies to CLIENT as requested. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -17- 

 11.1.3 As between the Parties, CLIENT is hereby the sole and exclusive owner of all inventions,
developments, improvements, know how and discoveries that are (i) made, conceived or reduced to practice in the course of or resulting from this Agreement by either Party or its subcontractors or agents alone or the Parties jointly and
(ii) (a) are solely related to the Product or to the Process or (b) are based on, an improvement to or direct derivative of, or incorporates CLIENT Intellectual Property or CLIENT Confidential Information or (c) not LWI New IP
(“CLIENT New IP”). LWI hereby assigns to CLIENT at its own cost all of LWI’s right, title, and interest in and to such CLIENT New IP and shall ensure that its employees, agents and subcontractors do the same. 

11.1.4 As between the Parties, LWI is hereby the sole and exclusive owner of all inventions, developments, improvements and discoveries that
are (i) made, conceived or reduced to practice in the course of or resulting from this Agreement by LWI and (ii) are not solely related to the Product or Process and are not an improvement to or direct derivative of, or incorporate CLIENT
Intellectual Property or CLIENT Confidential Information, and (a) are useful for the manufacture of other products and processes other than the Product and Process or relates generally to LWI’s business of developing or producing
biological materials or (b) are based on, an improvement or direct derivative of, or incorporates LWI Intellectual Property or LWI Confidential Information (“LWI New IP”). CLIENT hereby assigns to LWI all of CLIENT’s
right, title, and interest in and to such LWI New IP. 
 11.1.5 LWI shall [ * ]. 

11.2 License Grants. 

11.2.1 During the term of this Agreement, CLIENT hereby grants to LWI the right to use for its performance under this Agreement all CLIENT
Intellectual Property provided to it that is necessary for LWI to perform its obligations under this Agreement for the sole and limited purpose of LWI’s performance of its obligations under this Agreement, including, without limitation, the
development of the Process, Master Production Record and Specifications, and the manufacture of Product for CLIENT. 
 11.2.2 LWI hereby
grants to CLIENT an irrevocable, fully paid, non-exclusive worldwide license, with the right to grant and authorize sublicenses through multiple layers of sublicensees, under any and all LWI Intellectual Property (including without limitation LWI
New IP) that LWI incorporates pursuant to this Agreement into the Process, Master Production Record and Specifications, to make, have made, use, have used, sell, offer for sale, have sold, import, have imported, export, have exported, develop, have
developed, commercialize and have commercialized any GVAX product including without limitation the Product; provided, however, if CLIENT sublicenses, either directly or through multiple layers of sublicensees, such license to a Third Party
manufacturer, which manufacturer (i) [ * ] or (ii) [ * ], then, in either of such instances, the following additional terms shall apply: (a) prior to any such sublicense or transfer of such LWI Intellectual Property to a
Third Party [ * ], the Parties shall enter into a three-way confidentiality 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -18- 

 
agreement between CLIENT, LWI, and the Third Party, which shall limit such Third Party’s use of such LWI Intellectual Property (and LWI New IP in accordance with the provisions set forth
below) to manufacturing Product for CLIENT on terms of confidentiality and non-use at least as stringent as those set forth herein, (b) any related technology transfer of documentation or CLIENT Process from LWI’s facility to another Third
Party shall be at [ * ] expense, and (c) CLIENT and LWI shall negotiate in good faith and, if agreed, CLIENT shall pay a reasonable technology transfer fee and/or royalty (if any) to LWI, which royalty [ * ], and which is
consistent with industry standards. In no event shall the total amount of transfer fees and/or royalties exceed [ * ] for all such payments to LWI. Should the parties fail to reach an agreement on such transfer fees and/or royalties, CLIENT
shall notify LWI in writing of its intent to use alternative, independently derived processes instead of the LWI Intellectual Property and no such LWI Intellectual Property shall be transferred. Notwithstanding the foregoing, in no event shall the
license granted herein include LWI Operating Documents unless specifically granted in writing by LWI in its sole discretion. If any such sublicense or transfer of LWI New IP occurs [ * ] years or more after the creation of such LWI New IP,
the royalty obligation set forth herein shall not apply to such LWI New IP. 
 11.3 Further Assurances. Each Party agrees to take all
necessary and proper acts, and will cause its employees, Affiliates, contractors, and consultants to take such necessary and proper acts, to effectuate the ownership provisions set forth in this Article 11. 

11.4 Prosecution of Patents. 

11.4.1 LWI will have the sole right and discretion to file, prosecute and maintain patent applications and patents claiming LWI New IP at
LWI’s expense. CLIENT will cooperate with LWI to file, prosecute and maintain patent applications and patents claiming LWI New IP, and will have the right to review and provide comments to LWI relating to such patent applications and patents.

 11.4.2 CLIENT will have the sole right and discretion to file, prosecute and maintain patent applications and patents claiming CLIENT New
IP at CLIENT’s expense. LWI will cooperate with CLIENT to file, prosecute and maintain patent applications and patents claiming CLIENT New IP, and will have the right to review and provide comments to CLIENT relating to such patent applications
and patents. 
  

	12.	REPRESENTATIONS AND WARRANTIES 

 12.1 By
CLIENT. CLIENT hereby represents and warrants to LWI that (i) it has the requisite power and authority to enter into this Agreement and perform its obligations hereunder, (ii) it has the requisite intellectual property and legal rights
related to the CLIENT Development Materials and the Product to authorize the performance of LWI’s obligations under this Agreement related thereto, and (iii) the performance of the Statement of Work and the production by LWI of the Product
as contemplated in this Agreement will not give rise to a potential cause of action by a Third Party against LWI for infringement or another violation of intellectual property rights based upon use of the CLIENT Development Materials. Such
representation and warranty will not apply to any production equipment supplied by LWI, or LWI Intellectual Property. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -19- 

 12.2 By LWI. LWI hereby represents and warrants to CLIENT that (i) it has the
requisite power and authority to enter into this Agreement and perform its obligations hereunder, (ii) it has the requisite intellectual property rights, including without limitation in its equipment and Facility, to be able to perform its
obligations under this Agreement, (iii) LWI’s use of its equipment and Facility as contemplated in this Agreement will not give rise to a potential cause of action by a Third Party against CLIENT for infringement or another violation of
intellectual property rights, (iv) LWI will not incorporate into the Product or utilize in connection with this Agreement any Third Party Intellectual Property without the prior consent of CLIENT unless CLIENT provides to LWI any Third Party
Intellectual Property for incorporation into Product, and (v) the Product does not include, and was not manufactured by LWI utilizing, any Third Party Intellectual Property, unless such Third Party Intellectual Property was provided or approved
in writing by CLIENT for use in Product, including as part of the CLIENT Development Materials. LWI represents and certifies it will not use in any capacity the services of any person, or organization that employs any person that is or has been
debarred under Section 306 of the Generic Drug Enforcement Act, is an excluded party from doing business with the U.S. Federal Government (Excluded Parties List System published by GSA), Office of Inspector General’s List of Excluded
Individuals/Entities (LEIE), is included on any other government exclusion list of persons or entities with whom U.S. companies and individuals are prohibited from doing business with (e.g. OFAC List of Blocked Persons), is similarly debarred or
excluded under the Applicable Law in any other jurisdiction. Upon written request of CLIENT, LWI shall, within [ * ] business days, provide written confirmation that it has complied with the foregoing obligation. LWI agrees to promptly
disclose in writing to CLIENT if any employee or agent is debarred or excluded, or if any action or investigation is pending or, to the best of its knowledge, threatened, relating to the debarment or exclusion of it or any person performing services
related to this Agreement. 
  

	13.	DISCLAIMER; LIMITATION OF LIABILITY 

13.1 DISCLAIMER. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY
WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, WITH RESPECT TO PRODUCT OR MATERIALS. LWI SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY
WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE WITH RESPECT TO PRODUCT AND MATERIALS. 
 13.2 Disclaimer
of Consequential Damages. [ * ], IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ANY OF ITS AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES OR FOR LOST PROFITS, BUSINESS OR GOODWILL
SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES IN CONNECTION WITH THIS AGREEMENT, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

13.3 Limitation of Liability. [ * ], BOTH PARTIES HEREBY AGREE THAT TO THE FULLEST EXTENT PERMITTED BY LAW, EACH PARTY’S
LIABILITY TO THE OTHER PARTY FOR ANY AND ALL CLAIMS, LOSSES, EXPENSES, OR DAMAGES 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -20- 

 
ARISING OUT OF OR IN ANY WAY RELATED TO A STATEMENT OF WORK FROM ANY CAUSE OR CAUSES, INCLUDING, BUT NOT LIMITED TO, NEGLIGENCE, ERRORS, OMISSIONS OR STRICT LIABILITY, SHALL NOT EXCEED THE [ *
] AND EACH PARTY’S LIABLITY TO THE OTHER PARTY FOR ANY AND ALL CLAIMS, LOSSES, EXPENSES, OR DAMAGES THAT [ * ], SHALL NOT EXCEED [ * ]. 

13.4 Certain Limited Exceptions. 

(a) NOTWITHSTANDING ANYTHING TO THE CONTRARY, NOTHING HEREIN SHALL LIMIT THE LIABILITY OF A PARTY IN RESPECT OF LIABILITIES, LOSSES, DAMAGES OR
COSTS ARISING FROM (I) FRAUD, GROSS NEGLIGENCE, WILLFUL MISCONDUCT, OR INTENTIONAL MISREPRESENTATION OR (II) [ * ] OR (III) A BREACH OF ANY CONFIDENTIALITY OR INTELLECTUAL PROPERTY PROVISION OR OBLIGATION. 

(b) FOR THE AVOIDANCE OF DOUBT, [ * ] 

13.5 TO THE EXTENT THAT ANY CLAUSE IN THIS ARTICLE 13 CONFLICTS WITH ANY OTHER CLAUSE IN THIS AGREEMENT, THE CLAUSE IN ARTICLE 13 SHALL TAKE
PRECEDENCE OVER SUCH CONFLICTING CLAUSE. IF APPLICABLE LAW PREVENTS ENFORCEMENT OF ANY CLAUSE IN ARTICLE 13, THEN SUCH CLAUSE SHALL BE DEEMED MODIFIED TO PROVIDE THE MAXIMUM PROTECTION FOR A PARTY AS IS ALLOWABLE UNDER APPLICABLE LAW. 

 

	14.	TERM AND TERMINATION 

 14.1 Term. The
term of this Agreement will commence on the Effective Date and will continue until the fifth anniversary of the Effective Date unless terminated prior to that time or extended by the Parties. 

14.2 Termination for Material Breach. Either Party may terminate this Agreement or Statement of Work, by written notice to the other
Party, for any material breach of, as the case may be, this Agreement or a Statement of Work by the other Party, if such breach is not cured within thirty (30) days after the breaching Party receives written notice of such breach from the
non-breaching Party; provided, however, that if such breach is capable of being cured, but not capable of being cured within such thirty-day period, and the breaching Party has commenced and diligently continued actions to cure such breach within
such thirty-day period, except in the case of a payment default, the cure period shall be extended to [ * ] days, so long as the breaching Party is making diligent efforts to do so. Such termination shall be effective upon expiration of such
cure period. 
  
 [*] = Certain confidential information contained in this document,
marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -21- 

 14.3 Termination by Notice. 

14.3.1 Without Cause. 
 (a)
By CLIENT. Subject to the fees set forth in Section 14.6.3, CLIENT may terminate this Agreement or any Statement of Work by providing at least [ * ] days’ prior written notice of termination to LWI. 

(b) By LWI. LWI may terminate this Agreement by providing [ * ] months’ prior written notice of termination to CLIENT provided
that no such termination shall be effective until [ * ] months after the Effective Date of this Agreement and provided further that any Statement of Work, the duration of which extends beyond the termination of this Agreement, will upon the
request of CLIENT continue to be performed for the term of such Statement of Work, and will continue to be governed by the terms of this Agreement. For the avoidance of doubt, in the event of termination by LWI pursuant to this Section 14.3.1,
any royalty agreed to in connection with Section 11.2.2 [ * ] and LWI shall transfer the Process to a Third Party [ * ]. 

14.3.2 Other Termination. Subject to the fees set forth in Section 14.6.3, CLIENT may terminate this Agreement or a Statement of
Work (i) upon [ * ] days’ prior written notice to LWI in the event that [ * ], (ii) upon [ * ] days’ prior written notice to LWI pursuant to Section 2.2, or (iii) upon prior written notice to LWI
after the expiration of the period set forth in Section 17.2. 
 14.4 Termination by Insolvency. Either Party may terminate this
Agreement or a Statement of Work upon notice to the other Party, upon (a) the dissolution, termination of existence, or liquidation of the other Party; (b) the appointment of a custodian or receiver for the other Party who has not been
terminated or dismissed within ninety (90) days of such appointment; (c) the institution by the other Party of any proceeding under national, federal or state bankruptcy, reorganization, receivership or other similar laws affecting the
rights of creditors generally or the making by such Party of a composition or any assignment for the benefit of creditors under any national, federal or state bankruptcy, reorganization, receivership or other similar law affecting the rights of
creditors generally, which proceeding is not dismissed within ninety (90) days of filing. All rights and licenses granted pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of
the United States Code, licenses of rights of “intellectual property” as defined therein. 
 14.5 Termination Generally.
LWI agrees that CLIENT has the right to require LWI to cease work under any Statement of Work during a termination notice period. In such event LWI and CLIENT shall meet and discuss the [ * ] that are reasonably required with respect to each
Statement of Work. 
 14.6 Effects of Termination. 

14.6.1 Accrued Rights. Termination of this Agreement for any reason will be without prejudice to any rights that have accrued to the
benefit of a Party prior to such termination. Such termination will not relieve a Party of obligations that are expressly indicated to survive the termination of this Agreement. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -22- 

 14.6.2 Disposition of Remaining CLIENT Property and Confidential Information. Upon
termination or expiration of this Agreement, LWI will store any Remaining CLIENT Property as set forth in Section 7.2 and, at CLIENT’s option, return or destroy any CLIENT Confidential Information in the possession or control of LWI.
Likewise, CLIENT will, at LWI’s option, return or destroy any LWI Confidential Information in the possession or control of CLIENT. Notwithstanding the foregoing provisions: (i) LWI may retain and preserve, at its sole cost and expense,
samples and standards of each Product following termination or expiration of this Agreement solely for use in determining LWI’s rights and obligations hereunder; and (ii) each Party may retain a single copy of the other Party’s
Confidential Information for documentation purposes only and which shall remain subject to the obligations of nonuse and confidentiality set forth in this Agreement. 

14.6.3 Payment. 
 (a) In
the event of any termination of a Statement of Work or the Agreement, except termination by LWI under Section 14.3.1(b) or by CLIENT under Section 14.2, for the lesser of the estimated term remaining under the applicable Statement of Work
or [ * ] months from the date of receipt of notice of termination (in the event of termination by CLIENT in connection with Section 2.2, the [ * ] months shall be reduced to [ * ]) (the “Termination Fee Period”),
CLIENT shall pay to LWI all documented costs incurred by LWI consisting of the following, but not exceeding any aggregate estimate in the applicable Statement of Work: (i) out-of-pocket losses to LWI for purchase of unmarketable or and
unreturnable materials which have become unusable by reason of termination, (ii) all uncancellable labor commitments specifically agreed in the applicable Statement of Work, (iii) suite fees assuming the suite is not used by another LWI
client at comparable rates and for a comparable term, (iv) all work or Product in process and all fees for professional services set forth in the applicable Statement of Work rendered through the effective date of such termination of the
applicable Statement of Work and (v) reasonable wind-down costs, including, but not limited to, LWI labor costs directly associated with the applicable Statement of Work. LWI shall invoice CLIENT for the fees set forth in Sections 14.6.3(a)(ii)
and (iii) and 14.6.3(a)(v) on a monthly basis until the earlier of the expiration of, as the case may be, the Termination Fee Period or LWI’s use of the suite for another client at comparable rates and for a comparable term. LWI shall use
commercially reasonable efforts to mitigate the damages set forth herein. 
 (b) For the avoidance of doubt, in the event of termination by
LWI pursuant to this Section 14.3.1(b) or by CLIENT pursuant to Section 14.2, [ * ] shall not apply. 
 14.6.4
Survival. Sections 2.3.2, 2.3.3, the last sentence of 4.3, 4.5, 4.6, 4.7, 5, 6, 7, the last sentence of 8.1, 8.3, 8.4, 10, 11, 12, 13, 14.6, 15, and 16, and, as relevant, Sections 1 and 17 of this Agreement, together with any appendices
referenced therein, will survive any expiration or termination of this Agreement. 
  

	15.	INDEMNIFICATION 

 15.1 Indemnification of CLIENT. LWI will
indemnify CLIENT, its Affiliates, and their respective directors, officers, employees and agents, and defend and hold each of them harmless, from and against any and all losses, damages, liabilities, costs and expenses (including reasonable
attorneys’ fees and expenses) in connection with any and all liability suits, 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -23- 

 
investigations, claims or demands (collectively, “Losses”) to the extent such Losses arise out of or result from any claim, lawsuit or other action or threat by a Third Party
arising out of: (a) any material breach by LWI of this Agreement, or (b) the negligence or willful misconduct on the part of one or more of the LWI Parties in performing any activity contemplated by this Agreement, except for those Losses
for which CLIENT has an obligation to indemnify the LWI Parties pursuant to Section 15.2, as to which Losses each Party will indemnify the other to the extent of their respective liability for the Losses. 

15.2 Indemnification of LWI. CLIENT will indemnify LWI and its Affiliates, and their respective directors, officers, employees and
agents (the “LWI Parties”), and defend and hold each of them harmless, from and against any and all Losses to the extent such Losses arise out of or result from any claim, lawsuit or other action or threat by a Third Party arising
out of: (a) any material breach by CLIENT of this Agreement, (b) the use or sale of Products (including any infringement of Third Party intellectual property rights), except to the extent such Losses arise out of or result from a breach by
LWI of Section 5.1 or 12.2, (c) the negligence or willful misconduct on the part of CLIENT or its Affiliates in performing any activity contemplated by this Agreement, or (d) the use or practice by LWI of any process, invention or
other intellectual property supplied by CLIENT to LWI under this Agreement, except for those Losses for which LWI has an obligation to indemnify CLIENT pursuant to Section 15.1, as to which Losses each Party will indemnify the other to the
extent of their respective liability for the Losses. 
 15.3 Indemnification Procedure. 

15.3.1 An “Indemnitor” means the indemnifying Party. An “Indemnitee” means the indemnified Party, its
Affiliates, and their respective directors, officers, employees and agents. 
 15.3.2 An Indemnitee which intends to claim indemnification
under Section 15.1 or Section 15.2 hereof shall promptly notify the Indemnitor in writing of any claim, lawsuit or other action in respect of which the Indemnitee, its Affiliates, or any of their respective directors, officers, employees
and agents intend to claim such indemnification. The Indemnitee shall permit, and shall cause its Affiliates and their respective directors, officers, employees and agents to permit, the Indemnitor, at its discretion, to settle any such claim,
lawsuit or other action and agrees to the complete control of such defense or settlement by the Indemnitor; provided, however, that in order for the Indemnitor to exercise such rights, such settlement shall not adversely affect the Indemnitee’s
rights under this Agreement or impose any obligations on the Indemnitee in addition to those set forth herein. No such claim, lawsuit or other action shall be settled without the prior written consent of the Indemnitor and the Indemnitor shall not
be responsible for any legal fees or other costs incurred other than as provided herein. The Indemnitee shall cooperate fully with the Indemnitor and its legal representatives in the investigation and defense of any claim, lawsuit or other action
covered by this indemnification, all at the reasonable expense of the Indemnitor. The Indemnitee shall have the right, but not the obligation, to be represented by counsel of its own selection and expense. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -24- 

 15.4 Insurance. 

15.4.1 CLIENT will maintain, at all times during the term of this Agreement and for five years thereafter, a products liability insurance
policy (the “Insurance Policy”), with a per occurrence limit of at least five million dollars ($5,000,000) and an aggregate limit of at least five million dollars ($5,000,000), and will provide a certificate of insurance to LWI that
the Insurance Policy has been endorsed to designate LWI as an additional insured. CLIENT will maintain the Insurance Policy with an insurance company having a minimum AM Best rating of A. CLIENT will provide LWI with at least [ * ] days’
written notice prior to termination of such Insurance Policy. 
 15.4.2 LWI will maintain, at all times during the term of this Agreement
and for five years thereafter, a liability insurance policy (the “LWI Insurance Policy”), with a per occurrence limit of at least five million dollars ($5,000,000) and an aggregate limit of at least ten million dollars
($10,000,000), and will provide a Certificate of Insurance to CLIENT that the LWI Insurance Policy has been endorsed to designate CLIENT as an additional insured. LWI will maintain the Insurance Policy with an insurance company having a minimum AM
Best rating of A. LWI will provide CLIENT with at least [ * ] days’ written notice prior to termination of such LWI Insurance Policy. 
  

	16.	NON-SOLICITATION 

 During the term of a Statement of Work
and for [ * ] months thereafter, each of the Parties agrees not to seek to induce or solicit any employee of the other Party or its Affiliate who performed substantial services related the Statement of Work to discontinue his or her
employment with the other Party or its Affiliate in order to become an employee or an independent contractor of the soliciting Party or its Affiliate; provided, however, that neither Party shall be in violation of this Section 16 as a result of
making a general solicitation for employees or independent contractors. For the avoidance of doubt, the publication of an advertisement shall not constitute solicitation or inducement. 

 

	17.	MISCELLANEOUS 

 17.1 Independent Contractors. Each of the Parties
is an independent contractor and nothing herein contained shall be deemed to constitute the relationship of partners, joint venturers, nor of principal and agent between the Parties. Neither Party shall at any time enter into, incur, or hold itself
out to Third Parties as having authority to enter into or incur, on behalf of the other Party, any commitment, expense, or liability whatsoever. 

17.2 Force Majeure. Neither Party shall be in breach of this Agreement if there is any failure of performance under this Agreement
(except for payment of any amounts due under this Agreement) occasioned by any reason beyond the control and without the fault or negligence of the Party affected thereby, including, without limitation, an act of God, fire, flood, act of government
or state, war, civil commotion, insurrection, acts of terrorism, embargo, sabotage, prevention from or hindrance in obtaining energy or other utilities, a shortage of raw materials or other necessary components, labor disputes of whatever nature, or
any other reason beyond the 
  
 [*] = Certain confidential information contained in
this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -25- 

 
control and without the fault or negligence of the Party affected thereby (a “Force Majeure Event”). Notwithstanding the foregoing, in the event of a complete or partial
regulatory shutdown of a facility or service or other act by an governmental or regulatory authority that (a) specifically impacts a Party’s operations (i.e., without shutting down facilities owned by Third Parties) and (b) is due to
a Party’s negligence, willful misconduct or non-compliance with Applicable Laws, such shutdown shall not constitute a “Force Majeure Event”. Such excuse shall continue as long as the Force Majeure Event continues. Upon cessation of
such Force Majeure Event, the affected Party shall promptly resume performance under this Agreement as soon as it is commercially reasonable for the Party to do so. Each Party agrees to give the other Party prompt written notice of the occurrence of
any Force Majeure Event, the nature thereof, and the extent to which the affected Party will be unable to fully perform its obligations under this Agreement. Each Party further agrees to use commercially reasonable efforts to correct the Force
Majeure Event as quickly as practicable (provided that in no event shall a Party be required to settle any labor dispute) and to give the other Party prompt written notice when it is again fully able to perform such obligations. In the event that a
Force Majeure Event prevents LWI from performing under this Agreement for more than [ * ] days, then CLIENT may terminate this Agreement without any further obligation to LWI. 

17.3 Notices. Any notice required or permitted to be given under this Agreement by any Party shall be in writing and shall be
(a) delivered personally, (b) sent by registered mail, return receipt requested, postage prepaid, (c) sent by a nationally-recognized courier service guaranteeing next-day or second day delivery, charges prepaid, or (d) delivered
by facsimile (with documented evidence of transmission), to the addresses or facsimile numbers of the other Party set forth below, or at such other addresses as may from time to time be furnished by similar notice by any Party. The effective date of
any notice under this Agreement shall be the date of receipt by the receiving Party. 
 If to LWI: 

Lonza Walkersville, Inc. 
 Attn:
Vice President, Cell Therapy Bioservice 
 8830 Biggs Ford Road 

Walkersville, Maryland 21793 

Fax: [ * ] 
 With a copy
to: 
 General Counsel 
 Lonza
America, Inc. 
 90 Boroline Road 

Allendale, NJ 07401 
 Fax: [ *
] 
  
 [*] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -26- 

 If to CLIENT: 

Aduro BioTech, Inc. 
 Justin
Skoble 
 626 Bancroft Way, 3C 

Berkeley, CA 94710 
 Fax: [ *
] 
 With a copy to: Aduro Legal at the same address. 

Either Party may change its address for notice by giving notice thereof in the manner set forth in this Section 17.3. 

17.4 Entire Agreement; Amendments. This Agreement, including the Appendices attached hereto and referenced herein, constitutes the full
understanding of the Parties and a complete and exclusive statement of the terms of their agreement with respect to the specific subject matter hereof and supersedes all prior agreements and understandings, oral and written, among the Parties with
respect to the subject matter hereof. No terms, conditions, understandings or agreements purporting to amend, modify or vary the terms of this Agreement (including any Appendix hereto) shall be binding unless hereafter made in a written instrument
referencing this Agreement and signed by each of the Parties. 
 17.5 Governing Law. This Agreement will be governed by and construed
in accordance with the internal laws of the State of New York, without giving effect to its conflicts of laws provisions. The Parties consent to the exclusive jurisdiction of the state and federal courts in and for New York for any dispute or claim
arising from or relating to this Agreement. 
 17.6 Counterparts. This Agreement and any amendment hereto may be executed in any
number of counterparts, each of which shall for all purposes be deemed an original and all of which shall constitute the same instrument. This Agreement shall be effective upon full execution by facsimile or original, and a facsimile signature shall
be deemed to be and shall be as effective as an original signature. 
 17.7 Severability. If any part of this Agreement shall be
found to be invalid or unenforceable under applicable law in any jurisdiction, such part shall be ineffective only to the extent of such invalidity or unenforceability in such jurisdiction, without in any way affecting the remaining parts of this
Agreement in that jurisdiction or the validity or enforceability of the Agreement as a whole in any other jurisdiction. In addition, the part that is ineffective shall be reformed in a mutually agreeable manner so as to as nearly approximate the
intent of the Parties as possible. 
 17.8 Titles and Subtitles. All headings, titles and subtitles used in this Agreement (including
any Appendix hereto) are for convenience only and are not to be considered in construing or interpreting any term or provision of this Agreement (or any Appendix hereto). 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -27- 

 17.9 Exhibits. All “RECITALS”, “DEFINITIONS”, exhibits and appendices
referred to herein form an integral part of this Agreement and are incorporated into this Agreement by such reference. 
 17.10
Pronouns. Where the context requires, (i) all pronouns used herein will be deemed to refer to the masculine, feminine or neuter gender as the context requires, and (ii) the singular context will include the plural and vice versa.

 17.11 Assignment. This Agreement shall be binding upon the successors and assigns of the Parties and the name of a Party appearing
herein shall be deemed to include the names of its successors and assigns. Neither Party may assign its interest under this Agreement without the prior written consent of the other Party, such consent not to be unreasonably withheld; provided,
however, either party may be entitled without the prior written consent of the other Party to assign this Agreement to an Affiliate or to any company to which it has transferred all or substantially all of its assets or capital stock relating to the
activities contemplated under this Agreement, whether through purchase, merger, consolidation or otherwise; provided that in the event that CLIENT merges, is acquired, consolidates or sells all or substantially all of its business to which this
Agreement relates, such successor in interest is not an entity whose business primarily derives from providing contract manufacturing services. Any permitted assignment of this Agreement by either Party will be conditioned upon that Party’s
permitted assignee agreeing in writing to comply with all the terms and conditions contained in this Agreement. Any purported assignment without a required consent shall be void. No assignment shall relieve any Party of responsibility for the
performance of any obligation that accrued prior to the effective date of such assignment. 
 17.12 Waiver. The failure of any Party
at any time or times to require performance of any provision of this Agreement (including any Appendix hereto) will in no manner affect its rights at a later time to enforce the same. No waiver by any Party of any term, provision or condition
contained in this Agreement (including any Appendix hereto), whether by conduct or otherwise, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, provision or condition or of any other
term, provision or condition of this Agreement (including any Appendix hereto). 
 17.13 No Presumption Against Drafter. For purposes
of this Agreement, CLIENT hereby waives any rule of construction that requires that ambiguities in this Agreement (including any Appendix hereto) be construed against the drafter. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -28- 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.

  

			
	ADURO BIOTECH, INC.
		
	By:		 /s/ Stephen Isaacs

	Name:		Stephen Isaacs
	Title:		CEO
	
	LONZA WALKERSVILLE, INC.
		
	By:		 /s/ Stephan Kutzer

	Name:		Stephan Kutzer
	Title:		COO & President

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -29- 

 APPENDIX A 

STATEMENT OF WORK 
 TO
BE ATTACHED 
  
 [*] = Certain confidential information contained in this
document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -30- 

 APPENDIX B 

QUALITY AGREEMENT 
 TO
BE ATTACHED 
  
 [*] = Certain confidential information contained in this
document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 -31-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]